Other substances

Ritonavir

Retroviral protease inhibitor.

Phase of research

Emergency use authorization

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

309

AI-suggested references

Clinical trials

General information

Ritonavir is an antiviral protease inhibitor used for HIV infection prevention and treatment in a fixed-dose with lopinavir. It is also used for hepatitis B and C treatment in combination with other anti-viral drugs (ChEBI, LiverTox). Ritonavir is a known potent hepatic cytochrome P450 (CYP) 3A4 isoenzyme inhibitor (Cvetkovic and Goa, 2012). It also inhibits a variety of other human enzymes and therefore, upon therapy, drug interactions have to be considered (Heskin et al., 2022).

Lopinavir/ritonavir therapy used to be one of the antiviral therapies of COVID-19 recommended by China's National Health Commission guidelines. It is NO longer recomended, however (Gui-Qiang et al., 2021). On July 4, 2020, WHO announced that the lopinavir/ritonavir treatment arm of the Solidarity trial in hospitalized patients with COVID-19 was discontinued. RECOVERY trial chief investigators stated that based on NO clinical benefit to hospitalized COVID-19 patients treated with lopinavir/ritonavir, further patient recruitment was halted. A living WHO guideline on drugs for covid-19 (as of March 4, 2022) strongly recommends AGAINST the use of lopinavir/ritonavir combination for the treatment of COVID-19.

A therapy using ritonavir combined with nirmatrelvir (co-packaged and marketed under the name Paxlovid®), which was developed by Pfizer, was approved for the treatment of COVID-19 in the UK by MHRA, has been granted emergency use authorization by the FDA in the USA, and has been authorized for use in the EU by EMA. Ritonavir was shown to significantly boost nirmatrelvir's therapeutic concentration (Owen et al., 2021). An interim analysis of a phase II/III clinical trial suggests a significant decrease in hospitalization among outpatients who have begun Paxlovid® treatment within up to 5 days of COVID-19 symptoms’ onset (Mahase, 2021).

Ritonavir on DrugBank
Ritonavir on PubChem
Ritonavir on Wikipedia

Marketed as

PAXLOVID (co-packaged with Nirmatrelvir); KALETRA (fixed-dose with Lopinavir); LOPINAVIR AND RITONAVIR (fixed-dose with Lopinavir); NORVIR; RITONAVIR; BUSVIR; EMPETUS; NORMUNE

CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.	Patients		Combination of lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu Capsule (SFJDC, a traditional Chinese medicine)	Mar/16/2020
[Potential antiviral therapeutics for 2019 Novel Coronavirus].	Similar viruses		In combination with lopinavir or lopinavir and interferon-beta	Feb/05/2020
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.	Patients		14.9 % of patients received lopinavir/ritonavir therapy	Mar/13/2020
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.	Patients		Lopinavir-ritonavir combination was used to treat 5 patients also requiring supplemental oxygen. For 3 of the 5 patients, fever resolved and supplemental oxygen requirement was reduced within 3 days, whereas 2 deteriorated with progressive respiratory failure. Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.	Mar/03/2020
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study	Patients		Used as lopinavir/ritonavir (Days 1–14: 400 mg/100 mg twice daily) plus IFN-α by aerosol inhalation (5 million U twice daily). Less effective than favipiravir plus IFN-α.	Mar/18/2020
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	in silico			Feb/18/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico		Oral, in combination with lopinavir: lopinavir/ritonavir 200 mg/50 mg/capsule, 2 capsules each time, 2 times/day Oral, in combination with lopinavir: lopinavir/ritonavir 200 mg/50 mg/capsule, 2 capsules each time, 2 times/day	Feb/22/2020
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients Preprint	Patients		in combination with danoprevir	Mar/24/2020
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19 Preprint	Patients		Better in combination with Novaferon and Lopinavir than only with Lopinavir	Apr/29/2020
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial Small molecule Randomized controlled open trial	Patients	3.62	lopinavir/ritonavir (400mg/100mg, bid, po.) in combination with interferon alpha inhalation (100,000 iu, tid or qid)	Oct/25/2020
Using Integrated Computational Approaches to Identify Safe and Rapid Treatment for SARS -CoV- 2	in silico		drug which can construct a covalent bond with Cys145 inside binding site SARS-CoV-2 main protease	May/04/2020
IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	in silico		optimal combination therapy against SARS-CoV-2 was comprised of remdesivir, ritonavir, and lopinavir	May/08/2020
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production Preprint	VERO E6 cell cultures		in combination with atazanavir	Apr/06/2020
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	Patients		Combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days is better than lopinavir-ritonavir in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19	May/08/2020
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms	in silico			Apr/15/2020
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. Case report	Patients	1.72	Combination of lopinavir/ritonavir (Kaletra, AbbVie)	Feb/17/2020
Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation 3CLpro Small molecule In silico	in silico	5.07	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Aug/04/2020
Potential protease inhibitors and their combinations to block SARS-CoV-2 3CLpro TMPRSS2 Cathepsin B Cathepsin L Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease and the host's TMPRSS protease.	Sep/14/2020
Effectiveness of lopinavir/ritonavir on covid-19 related pneumonia in a child with Covid-19 associated Kawasaki disease Small molecule Case report	Kawasaki disease child patient	0.84	In a fixed-dose with lopinavir. Overall clinical improvement in a 10-year-old patient with COVID-19-associated Kawasaki disease after lopinavir/ritonavir treatment (preceded by unsuccessful hydroxychloroquine and oseltamivir treatment). Dosage: 75 mg daily for 14 days.	Nov/13/2020
Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs 3CLpro nsp14 Small molecule In silico	in silico	5.16	Predicted to bind the active site of the SARS-CoV-2 nsp14 exoribonuclease and possibly also of the 3C-like protease. Ritonavir was suggested to potentiate the effect of antivirals acting on viral RNA polymerization.	Dec/09/2020
CSF3 Is a Potential Drug Target for the Treatment of COVID-19 Small molecule In vitro In silico	16+ years old volunteers	3.37	Decreased host CSF3 protein expression in vitro and was predicted to inhibit it. CSF3 was computationally modelled to represent a drug target for the treatment of COVID-19.	Jan/22/2021
Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease 3CLpro Small molecule In silico	in silico	1.77	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Dec/11/2020
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development AI Small molecule In vitro In silico	in silico (AI); AC16 and THLE-2 cells (cytotoxicity); Vero E6 cells	6.09	Based on computational assessment and in vitro validation,	Nov/10/2020
In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors 3CLpro Small molecule In silico	in silico	1.32	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jan/02/2021
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine... Small molecule Randomized controlled double-blind trial Moderate severity Mild severity	Mild to moderate COVID-19 patients	2.44	In combination with	Feb/09/2021
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 Crystallization Novel compound Biophysical assay Small molecule Enzyme assay Animal model In vitro Mechanism Phase I clinical trial Randomized controlled double-blind trial	Crystallization; Biophysical assay; Enzyme assay; Vero E6 cells; hACE2-A549 cells; dNHBE cells; Vero76 cells; BALB/c mice; SD rats and Cynomolgus monkeys (metabolic studies); SARS-CoV-2 MA10 (mouse-adapted); healthy adults; SARS-CoV-2 (USA_WA1/2020)	47.73	Ritonavir was shown to significantly boost nirmatrelvir’s therapeutic concentration. Dosage: 3 doses of 100 mg 12 hour apart.	Nov/02/2021

AI-suggested references

Link	Publication date
[Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].	Jul/20/2021
Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.	Feb/15/2021
Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.	Oct/13/2021
Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.	Jan/28/2021
The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment	Oct/24/2021
Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone.	Sep/30/2021
Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.	Apr/06/2022
[Clinical study of artesunate in the treatment of coronavirus disease 2019].	Jun/13/2020
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronavirUs Infection requiring hospiTalization (BISCUIT)"].	Jul/30/2020
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.	Feb/23/2022
Targeting allosteric pockets of SARS-CoV-2 main protease Mpro.	Feb/27/2021
Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.	Nov/07/2020
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.	Jun/04/2020
Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs.	May/03/2022
[The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].	Apr/27/2020
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.	Jun/23/2020
Potential of 24-Propylcholestrol as Immunity Inducer against Infection of COVID-19 Virus: In Silico Study Immunomodulatory Drugs.	Dec/05/2022
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.	Nov/26/2020
Drug treatment options for the 2019-new coronavirus (2019-nCoV).	Dec/16/2021
Multidomain drug delivery systems of beta-casein micelles for the local oral co-administration of antiretroviral combinations.	Aug/22/2021
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.	Apr/03/2022
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.	Feb/20/2021
Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.	Jan/04/2021
Disposition of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV-2 3CL Protease, across Animals and Humans.	Jan/20/2022
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.	Jun/27/2020
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?	Nov/30/2021
Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.	Jan/29/2021
Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.	May/12/2022
Cannabidiol Inhibits In Vitro Human Liver Microsomal Metabolism of Remdesivir: A Promising Adjuvant for COVID-19 Treatment.	Jun/16/2020
Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.	May/06/2020
Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.	Mar/02/2021
The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking.	Aug/26/2020
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.	Aug/08/2020
Structural Bioinformatics Used to Predict the Protein Targets of Remdesivir and Flavones in SARS-CoV-2 Infection.	Oct/08/2021
In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.	Jan/05/2021
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.	Apr/21/2020
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].	Feb/19/2021
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.	Jul/02/2021
Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.	Sep/20/2021
Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).	Aug/07/2020
Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.	Aug/27/2021
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.	Nov/02/2021
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.	Dec/03/2021
Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.	Oct/08/2020
Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 Mpro by large-scale molecular dynamic simulations combined with accurate binding free energy calculations.	Apr/26/2021
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.	Feb/25/2021
Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.	Jan/29/2021
Here we go again? A new pandemic of the 21st century.	Jul/16/2020
The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.	Jan/06/2022
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.	May/27/2022
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.	Mar/03/2020
Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.	May/15/2020
Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.	Oct/08/2020
Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19	Sep/29/2021
In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2	Apr/01/2022
Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial	Mar/22/2022
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.	May/03/2020
Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.	Aug/13/2020
Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies	Jul/28/2020
Low-dose radiation therapy in the management of COVID-19 pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial	Mar/31/2022
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab	Jun/02/2020
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice	Aug/29/2020
Computer Aided Drug Design Approach to Screen Phytoconstituents of Adhatoda vasica as Potential Inhibitors of SARS-CoV-2 Main Protease Enzyme	Feb/20/2022
Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports	Jul/20/2020
Computational Screening of Phenylamino-Phenoxy-Quinoline Derivatives against the Main Protease of SARS-CoV-2 Using Molecular Docking and the ONIOM Method	Sep/22/2021
SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN	Jan/10/2022
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coron	Jul/14/2020
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies	Nov/18/2021
Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.	Sep/28/2020
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form	Nov/21/2020
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients	Jun/05/2021
Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis.	Jun/25/2021
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients	Jul/28/2021
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial	Feb/24/2021
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants	Apr/22/2022
Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD	Feb/18/2021
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.	Apr/13/2021
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use	May/05/2020
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo	Aug/28/2021
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.	Oct/13/2020
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.	Aug/28/2020
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations	Aug/24/2021
Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease	Apr/01/2022
Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study	Aug/11/2021
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial	Mar/24/2022
Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.	Jun/22/2020
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	Mar/02/2022
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial	Nov/10/2021
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection	Nov/23/2020
Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations.	Jul/07/2021
RNAi to treat SARS-CoV-2:variant proofing the next generation of therapies	Mar/25/2021
No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.	Apr/22/2021
On a knife's edge of a COVID-19 pandemic: is containment still possible?	Mar/09/2020
Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus	Dec/01/2021
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study	May/13/2020
Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China	May/06/2020
Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study	May/14/2020
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19	Feb/01/2022
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments	Feb/02/2021
Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19.	Jun/24/2020
Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019	Apr/10/2020
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.	Jun/10/2021
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.	Aug/24/2020
Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.	Jul/30/2020
Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients	Jul/26/2021
The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults	Feb/10/2021
Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial.	Aug/24/2020
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan	Apr/03/2020
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial	Sep/14/2021
Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors	Jul/24/2020
Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants	Dec/07/2021
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.	Jul/18/2020
Protease Inhibitor Use in COVID-19.	Aug/14/2020
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia	Aug/09/2021
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients	Jul/29/2021
Comparative therapeutic efficacy of interferon alpha-2b and combination lopinavir/ritonavir plus interferon alpha-2b against SARS-CoV-2.	Aug/30/2021
Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation	Mar/05/2021
Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study	Jun/30/2020
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir	Aug/04/2020
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus	Apr/21/2020
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation	Aug/03/2021
Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn.	Oct/15/2020
Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019	Jun/18/2020
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?	Feb/09/2022
In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.	Aug/03/2020
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.	Sep/04/2021
Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (Mpro): An integrated computational approach.	May/29/2021
Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.	Oct/14/2020
Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic	Dec/04/2020
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19	Mar/04/2021
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study	Jul/30/2021
First-generation Oral Antivirals Against SARS-CoV-2.	May/08/2022
High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19	Jul/01/2021
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients.	Oct/23/2020
Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics	Sep/08/2021
Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China	Feb/01/2022
In silico evidence of antiviral activity against SARS-CoV-2 main protease of oligosaccharides from Porphyridium sp.	Mar/25/2021
Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach.	Sep/24/2020
Anticipated pharmacological role of Aviptadil on COVID-19	Nov/30/2021
Flavonoids from Siparuna cristata as Potential Inhibitors of SARS-CoV-2 Replication.	Jul/20/2021
Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings	May/13/2021
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome	Sep/24/2020
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia	Sep/30/2021
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019	Aug/24/2020
Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan.	Apr/30/2020
Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.	Oct/25/2020
Potential specific therapies in COVID-19	May/22/2020
Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis	Jan/31/2022
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19	Sep/17/2020
Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study	Jun/23/2021
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.	May/11/2021
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study	May/04/2022
Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial	Oct/06/2021
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19	Apr/12/2022
Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine	Nov/06/2021
Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study	Sep/24/2020
Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.	Apr/09/2021
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomi	Dec/07/2020
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.	Jun/14/2021
Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.	Jul/31/2020
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns	May/30/2020
Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics	Jul/22/2021
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019	May/16/2020
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir	Aug/25/2021
Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.	Nov/23/2021
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial	Nov/12/2020
Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy	Jan/20/2021
Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?	Aug/27/2021
Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2	Sep/13/2020
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection	Nov/16/2021
A retrospective comparison of drugs against COVID-19	Dec/14/2020
Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).	Nov/11/2020
Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters	Dec/09/2021
Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy	Apr/14/2021
Drug repurposing approach to fight COVID-19	Sep/05/2020
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.	Oct/01/2020
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection	Nov/04/2021
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial	Feb/11/2021
Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy	Nov/11/2021
All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study	Jun/24/2021
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment	Oct/06/2020
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?	Mar/08/2021
Safety profile of COVID-19 drugs in a real clinical setting	Oct/06/2021
Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.	Nov/09/2020
Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT study	Apr/27/2022
Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.	Sep/25/2020
Tocilizumab in HIV patient with severe COVID-19: case report	Oct/16/2021
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production	Sep/21/2020
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19	Feb/25/2021
Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study	Jan/11/2022
Potential therapeutic agents against COVID-19: What we know so far	Apr/04/2020
Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface	Jan/25/2021
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.	Nov/26/2020
Nirmatrelvir Plus Ritonavir: First Approval	Mar/20/2022
Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Mar/17/2020
Peptide-like and small-molecule inhibitors against Covid-19	Sep/18/2021
Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.	Dec/26/2020
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study	May/04/2022
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients	Sep/12/2020
Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.	Mar/24/2021
Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases	Nov/05/2021
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	May/10/2020
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.	Sep/21/2020
Na+/K+-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection	Dec/14/2020
[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality].	Jul/09/2020
SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.	Aug/03/2020
Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock	May/02/2020
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).	Nov/23/2021
The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial	Dec/30/2020
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	Apr/03/2020
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19	Apr/28/2020
The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.	May/06/2021
Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir	Sep/28/2020
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.	Jan/28/2021
Phytochemicals against SARS-CoV as potential drug leads.	Dec/10/2020
Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?	Jul/21/2020
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients	Apr/17/2020
Teicoplanin: an alternative drug for the treatment of COVID-19?	Mar/13/2020
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients	Nov/01/2021
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection	Jul/16/2020
Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.	Dec/31/2020
Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection	Jul/31/2020
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.	Nov/10/2020
Optimal Drug Regimen and Combined Drug Therapy and Its Efficacy in the Treatment of COVID-19: A Within-Host Modeling Study.	May/19/2022
Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality	Oct/09/2020
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19.	May/26/2021
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients	Aug/02/2021
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.	Aug/10/2020
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study	Jun/23/2021
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.	Sep/01/2020
Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series	Jul/23/2020
Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients	Oct/13/2020
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Feb/16/2021
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir	Sep/22/2020
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics	Jun/14/2020
Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China.	Jan/30/2021
Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels	Apr/30/2022
Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients	Nov/25/2020
High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment	Apr/13/2020
Tiotropium Is Predicted to Be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis	Jul/20/2020
Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease	Sep/30/2020
Antiviral treatment of COVID-19	Jul/12/2021
Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019.	Oct/13/2020
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	Aug/23/2021
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.	Mar/15/2021
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients	Jan/31/2022
Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.	Dec/18/2020
Role of favipiravir in the treatment of COVID-19	Oct/30/2020
TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.	Oct/01/2020
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial	Jul/10/2021
Clinical trials on drug repositioning for COVID-19 treatment	Feb/08/2022
Efficacy of canakinumab in mild or severe COVID-19 pneumonia	Jan/19/2021
A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient	Jul/10/2020
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial	Jun/07/2020
A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19	Sep/18/2020
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial	Aug/10/2021
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir	Oct/26/2021
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets	Mar/24/2021
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients	Feb/09/2021
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial	Jun/30/2020
Insights on 3D Structures of Potential Drug-Targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking	Oct/28/2021
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs	Mar/23/2022
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients	Dec/03/2021
In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel:A Drug Antitarget	May/04/2021
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial.	Jun/29/2021
Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study	Feb/26/2021
Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19	Apr/29/2021
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective obser	Oct/15/2020
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19	Mar/18/2021
In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses	May/29/2020
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.	Jan/22/2021
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect	Apr/04/2022
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial	Feb/24/2022
Efficiency of antiviral treatment in COVID-19.	Apr/19/2021
Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19	Apr/26/2020
Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series	Oct/13/2020
Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models	Apr/30/2022
Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking	Jun/03/2021
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study	Sep/28/2020
Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules	Apr/19/2022
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience	Jan/18/2022
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review	Feb/22/2021
Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study	Nov/08/2021
Discovery of a new generation of angiotensin receptor blocking drugs: receptor mechanisms and in silico binding to enzymes relevant to covid-19.	Apr/09/2022
Candidate drugs against SARS-CoV-2 and COVID-19	Apr/29/2020
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study	Jun/25/2021
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis	Jul/11/2020
Tocilizumab and liver injury in patients with COVID-19.	Oct/07/2020
Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs	Feb/07/2022
Clinical Trials of Repurposed Antivirals for SARS-CoV-2	Aug/20/2020
Emerging small molecule antivirals may fit neatly into COVID-19 treatment	Oct/19/2021
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing	Jun/16/2020
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study	Jun/19/2020
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19	Jan/26/2021
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease	Jun/29/2020
Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.	Feb/20/2021
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs	Apr/20/2020
COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.	Jun/30/2020
Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19	Apr/17/2021
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations	Aug/20/2020
Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.	Apr/13/2021
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.	May/11/2021
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.	Oct/02/2020
Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR	Feb/17/2020
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid	May/21/2022
Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2	Oct/06/2020
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.	Nov/28/2020
Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective	Apr/01/2022
Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital.	Jul/31/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT05064800	PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants	Completed	Phase 1	Sep/21/2021	Dec/06/2021
Alternative id - C4671012 Interventions - Drug: Dabigatran\|Drug: PF-07321332/ritonavir + Dabigatran\|Drug: Ritonavir + Dabigatran Study type - Interventional Study results - No Results Available Locations - Research Centers of America ( Hollywood ), Hollywood, Florida, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 24 Age - 18 Years to 60 Years (Adult) Outcome measures - Area under the curve from time zero to infinity (AUCinf) of dabigatran when administer with PF-07321332/ritonavir\|Maximum Observed Plasma Concentration (Cmax) of dabigatran when administered with PF-07321332/ritonavir\|AUCinf of dabigatran when administered with multiple doses of ritonavir\|Cmax of dabigatran when administered with multiple doses of ritonavir\|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\|Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities\|Number of Participants With Clinically Significant Change From Baseline in Vital Signs\|Number of Participants With Abnormalities in Physical Examination\|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings\|Time to Reach Maximum Observed Plasma Concentration (Tmax) of dabigatran\|Plasma Decay Half-Life (t1/2) of dabigatran\|Cmax of PF-07321332\|AUCtau (area under the curve of the dosing interval) of PF-0321332\|Tmax of PF-0321332\|T1/2 of PF-0321332\|Apparent Oral Clearance (CL/F) of PF-0321332\|Apparent Volume of Distribution (Vz/F) of PF-0321332
NCT04291729	Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection	Completed	Phase 4	Feb/17/2020	Mar/19/2020
Alternative id - ASC-CTP-NC-01 Interventions - Drug: Ganovo+ritonavir+/-Interferon nebulization Study type - Interventional Study results - No Results Available Locations - The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 11 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Rate of composite adverse outcomes\|Time to recovery\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no requiring supplemental oxygen\|Rate of undetectable New coronavirus pathogen nucleic acid\|Rate of mechanical ventilation\|Rate of ICU admission\|Rate of serious adverse event
NCT04251871	Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection	Recruiting	Not Applicable	Jan/22/2020	Jan/22/2021
Alternative id - 2020001D Interventions - Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules\|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) Study type - Interventional Study results - No Results Available Locations - The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 150 Age - 14 Years to 80 Years (Child, Adult, Older Adult) Outcome measures - The incidents of acute respiratory distress syndrome (ARDS) development\|The time to fever resolution rate\|Time to recovery of lung injury
NCT04350684	Umifenovir in Hospitalized COVID-19 Patients	Enrolling by invitation	Phase 4	Apr/15/2020	Apr/24/2020
Alternative id - Umifenovir in COVID-19 Interventions - Drug: Umifenovir\|Drug: Interferon-β 1a\|Drug: Lopinavir / Ritonavir\|Drug: Single Dose of Hydroxychloroquine\|Drug: Standards of Care Study type - Interventional Study results - No Results Available Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization\|Cumulative incidence of serious adverse events
NCT05011812	Study of PBI-0451 in Healthy Subjects.	Recruiting	Phase 1	Aug/14/2021	May/31/2022
Alternative id - PBI-0451-0001 Interventions - Drug: PBI-0451 Dose 1\|Drug: PBI-0451 Dose 2\|Drug: PBI-0451 Dose 3\|Drug: PBI-0451 Dose 4\|Drug: Ritonavir\|Drug: Midazolam\|Drug: Placebo\|Drug: PBI-0451\|Drug: PBI-0451 Dose 5 Study type - Interventional Study results - No Results Available Locations - Auckland City Hospital, Auckland, New Zealand Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 120 Age - 18 Years to 59 Years (Adult) Outcome measures - Number of subjects with treatment emergent adverse events (TEAEs) in Single Ascending Dose (SAD) compared to placebo\|Number of subjects with clinically significant change from Baseline in vital signs in SAD\|Number of patients with laboratory abnormalities in SAD\|Number of subjects with treatment emergent adverse events (TEAEs) in Multiple Ascending Dose (MAD) compared to placebo\|Number of subjects with clinically significant change from Baseline in vital signs in MAD\|Number of patients with laboratory abnormalities in MAD\|To collect ECG data for PBI-0451 for the purpose of concentration-QT/QTc modeling\|Plasma concentration of each dose of study drug to determine AUCinf in SAD\|Plasma concentration of each dose of study drug to determine AUClast in SAD\|Plasma concentration of each dose of study drug to determine %AUCexp in SAD\|Plasma concentration of each dose of study drug to determine CL/F in SAD\|Plasma concentration of each dose of study drug to determine CLss/F in MAD\|Plasma concentration of each dose of study drug to determine AUCtau in MAD\|Plasma concentration of each dose of study drug to determine Cmax in MAD\|Plasma concentration of each dose of study drug to determine Tmax in MAD\|Plasma concentration of each dose of study drug to determine Tlast in MAD\|Plasma concentration of each dose of study drug to determine Clast in MAD\|Plasma concentration of each dose of study drug to determine Ctau in MAD\|Plasma concentration of each dose of study drug to determine λz in MAD\|Plasma concentration of each dose of study drug to determine t1/2\|Plasma concentration of each dose of study drug to determine Vz/F
NCT05047601	A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection	Recruiting	Phase 3	Sep/09/2021	Apr/18/2022
Alternative id - C4671006\|2021-002894-24\|EPIC-PEP Interventions - Drug: PF-07321332\|Drug: Placebo for PF-07321332\|Drug: Placebo for Ritonavir\|Drug: Ritonavir Study type - Interventional Study results - No Results Available Locations - Cahaba Research, Inc., Pelham, Alabama, United States\|The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States\|The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States\|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States\|Hope Clinical Research, Canoga Park, California, United States\|Lightship, El Segundo, California, United States\|Ascada Health PC, Fullerton, California, United States\|Ark Clinical Research, Long Beach, California, United States\|American Institute of Research, Los Angeles, California, United States\|FOMAT Medical Research, Oxnard, California, United States\|Optimus Medical Group, San Francisco, California, United States\|South Bay Clinical Research Institute, Torrance, California, United States\|Hope Clinical Research (COVID Satellite Location), West Hills, California, United States\|Future Innovative Treatments, LLC, Colorado Springs, Colorado, United States\|BRB Health Group DBA Broward Research Center, Aventura, Florida, United States\|Synergy Healthcare, Bradenton, Florida, United States\|MOORE Clinical Research, Inc., Brandon, Florida, United States\|Innovative Research of West Florida, Inc., Clearwater, Florida, United States\|Herco Medical and Research Center Inc, Coral Gables, Florida, United States\|Advance Clinical Research Group, Cutler Bay, Florida, United States\|Beautiful Minds Clinical Research Center, Cutler Bay, Florida, United States\|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States\|Unlimited Medical Research Group, LLC, Hialeah Gardens, Florida, United States\|Qway Research, LLC, Hialeah, Florida, United States\|Eastern Research Inc, Hialeah, Florida, United States\|Inpatient Research Clinic, Hialeah, Florida, United States\|Doral Medical Research,LLC, Hialeah, Florida, United States\|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States\|Asclepes Research Centers, Lutz, Florida, United States\|Pro-Care Research Center, Corp., Miami Gardens, Florida, United States\|Lakes Research, LLC., Miami Lakes, Florida, United States\|Savin Medical Group, LLC, Miami Lakes, Florida, United States\|Angels Clinical Research Institute, Miami, Florida, United States\|Nova Life Med Spa, Miami, Florida, United States\|LCC Medical Research Institute, LLC, Miami, Florida, United States\|Premium Medical Research Corp, Miami, Florida, United States\|Global Health Clinical Trials Corp, Miami, Florida, United States\|South Florida Research Center, Inc., Miami, Florida, United States\|Suncoast Research Group, LLC, Miami, Florida, United States\|University of Miami Health System, Miami, Florida, United States\|I.V.A.M. Clinical & Investigational Center, LLC, Miami, Florida, United States\|Medical Research of Westchester Inc, Miami, Florida, United States\|C'A Research, Miami, Florida, United States\|ProLive Medical Research, Corp., Miami, Florida, United States\|Entrust Clinical Research, Miami, Florida, United States\|Reed Medical Research, Miami, Florida, United States\|Kendall South Medical Center, Inc., Miami, Florida, United States\|Clinical Site Partners, Inc dba CSP Miami, Miami, Florida, United States\|Coral Research Clinic Corp, Miami, Florida, United States\|Omega Research Orlando, Orlando, Florida, United States\|NAPA Research LLC, Pompano Beach, Florida, United States\|CDC Research Institute, LLC, Port Saint Lucie, Florida, United States\|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States\|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States\|Accel Research Sites - St. Petersburg Clinical Research Unit, Saint Petersburg, Florida, United States\|Professional Urgent Care Services, Saint Petersburg, Florida, United States\|USPA Advance Concept Medical Research Group LLC, South Miami, Florida, United States\|Asclepes Research Centers, Spring Hill, Florida, United States\|Sunrise Research Institute, Sunrise, Florida, United States\|Tampa General Hospital, Tampa, Florida, United States\|Santos Research Center, CORP, Tampa, Florida, United States\|Palm Beach Research Center, West Palm Beach, Florida, United States\|Clinical Site Partners, Inc, Winter Park, Florida, United States\|Research by Design, LLC, Chicago, Illinois, United States\|The South Bend Clinic Center for Research, South Bend, Indiana, United States\|Accellacare, Ames, Iowa, United States\|McFarland Clinic, PC, Ames, Iowa, United States\|WKB Family Medicine Associates, Bossier City, Louisiana, United States\|New Orleans Sinus Center (COVID-19 Testing), Marrero, Louisiana, United States\|Tandem Clinical Research GI, LLC, Marrero, Louisiana, United States\|Southern Clinical Research Associates, LLC, Metairie, Louisiana, United States\|MedPharmics LLC, Metairie, Louisiana, United States\|Willis-Knighton Health System, Shreveport, Louisiana, United States\|Michigan Center of Medical Research, Farmington Hills, Michigan, United States\|Jackson Medical Mall, Jackson, Mississippi, United States\|Lakeland Pharmacy, Branson W., Missouri, United States\|Price Cutter, Springfield, Missouri, United States\|Mercury Street Medical Group, PLLC, Butte, Montana, United States\|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States\|Quality Clinical Research Inc, Omaha, Nebraska, United States\|Quality Clinical Research, Omaha, Nebraska, United States\|Walmart, Las Vegas, Nevada, United States\|Excel Clinical Research, Las Vegas, Nevada, United States\|Walgreens, Las Vegas, Nevada, United States\|Meridian Clinical Research, LLC, Endwell, New York, United States\|NYC Health + Hospitals/Harlem, New York, New York, United States\|Monroe Biomedical Research, Monroe, North Carolina, United States\|Accellacare, Wilmington, North Carolina, United States\|Innovo Research: Wilmington Health, Wilmington, North Carolina, United States\|Premier Medical Group, Clarksville, Tennessee, United States\|PharmaTex Research, LLC, Amarillo, Texas, United States\|ARC Clinical Research at William Cannon, Austin, Texas, United States\|St Hope Foundation, Bellaire, Texas, United States\|Conroe Willis Medical Research, Conroe, Texas, United States\|South Texas Clinical Research, Corpus Christi, Texas, United States\|Brooke Army Medical Center, Fort Sam Houston, Texas, United States\|SingnatureCare Emergency Center, Houston, Texas, United States\|Trio Clinical Trials, LLC, Houston, Texas, United States\|C & R Research Services USA, Houston, Texas, United States\|Next Level Urgent Care, Houston, Texas, United States\|SMS Clinical Research, LLC, Mesquite, Texas, United States\|LinQ Research, LLC, Pearland, Texas, United States\|Epic Medical Research, Red Oak, Texas, United States\|Sun Research Institute, San Antonio, Texas, United States\|Endeavor Clinical Trials, LLC, San Antonio, Texas, United States\|BFHC Research, San Antonio, Texas, United States\|Tranquility Research, Webster, Texas, United States\|University of Utah Medical Center, Salt Lake City, Utah, United States\|TPMG Clinical Research, Newport News, Virginia, United States\|Centro Medico Viamonte SRL, Caba, Buenos Aires, Argentina\|DIM Clinica Privada, Ramos Mejia. La Matanza, Buenos Aires, Argentina\|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina\|Instituto Médico de la Fundación Estudios Clínicos (Fundación Estudios Clínicos), Rosario, Santa FE, Argentina\|Sanatorio Britanico, Rosario, Santa FE, Argentina\|Instituto CAICI, Rosario, Santa FE, Argentina\|Hospital de Clinicas Presidente Nicolas Avellaneda, San Miguel de Tucuman, Tucuman, Argentina\|Clinica Mayo de UMCB SRL, San Miguel de Tucuman, Tucuman, Argentina\|Sanatorio Britanico S.A., Rosario, Argentina\|Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil\|Hospital Universitario Prof. Edgard Santos/ Universidade Federal da Bahia, Salvador, Bahia, Brazil\|Hospital Cardio Pulmonar, Salvador, Bahia, Brazil\|Chronos Pesquisa Clinica, Brasilia, Distrito Federal, Brazil\|AMB3 Serviços Médicos Ltda, Cuiabá, MATO Grosso, Brazil\|Hospital Luxemburgo - Associacao Mario Penna, Belo Horizonte, MG, Brazil\|Infection Control Ltda, Belo Horizonte, Minas Gerais, Brazil\|School of Medicine Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil\|Hospital Agamenon Magalhaes, Recife, Pernambuco, Brazil\|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, RIO Grande DO Norte, Brazil\|Hospital De Clinicas De Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil\|IBPClin- Instituto Brasil de Pesquisa Clinica, Rio de Janeiro, RJ, Brazil\|Instituto Nacional de Infectologia Evandro Chagas - INI/FIOCRUZ, Rio de Janeiro, RJ, Brazil\|CECOR - Centro Oncológico de Roraima, Boa Vista, Roraima/rr, Brazil\|Centro de Estudos Clinicos do Interior Paulista (CECIP), Jau, SAO Paulo, Brazil\|Hospital Dia do Pulmao, Blumenau, SC, Brazil\|Hospital Regional Hans Dieter Schmidt (HRHDS), Joinville, SC, Brazil\|Hospital e Maternidade Celso Pierro - PUC Campinas / Sociedade Campineira de Educação e Instruçã, Campinas, SP, Brazil\|Pesquisare Saude S/S Ltda, Santo André, SP, Brazil\|Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brazil\|Unidade Referenciada Oswaldo Cruz Vergueiro, São Paulo, SP, Brazil\|Hospital Heliópolis, São Paulo, SP, Brazil\|Instituto D'Or de Pesquisa e Ensino / Hospital São Luiz Jabaquara, São Paulo, SP, Brazil\|Scentryphar - Pesquisa Clínica, Campinas, SÃO Paulo, Brazil\|Associação Evangélica de Campinas - Hospital Samaritano, Campinas, SÃO Paulo, Brazil\|Instituto de Pesquisa Clínica de Campinas, Campinas, SÃO Paulo, Brazil\|Centro de Referência e Treinamento DST/AIDS, Sao Paulo, SÃO Paulo, Brazil\|Clinica de Alergia Martti Antila, Sorocaba, SÃO Paulo, Brazil\|CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, SÃO Paulo, Brazil\|Hospital Anchieta, São Bernardo do Campo, SÃO Paulo, Brazil\|CPCLIN - Centro de Pesquisas Clinicas Ltda, São Paulo, Brazil\|Instituto de Infectologia Emilio Ribas, São Paulo, Brazil\|Conjunto Hospitalar do Mandaqui, São Paulo, Brazil\|Individual Practice for Primary Medical Care - IPPMC - Dr. P. Panayotov EOOD, Burgas, Bulgaria\|MHAT St. Ekaterina, Dimitrovgrad EOOD, Dimitrovgrad, Bulgaria\|"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd, Haskovo, Bulgaria\|MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD, Kozloduy, Bulgaria\|Diagnostic-Consultative Center I Lom EOOD, Lom, Bulgaria\|Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD, Lom, Bulgaria\|Medical centre Leo Clinic EOOD, Lovech, Bulgaria\|MHAT Heart and Brain EAD, Pleven, Bulgaria\|UMHAT Sveta Marina - Pleven, Pleven, Bulgaria\|DCC Sveti Georgi EOOD, Plovdiv, Bulgaria\|MHAT "St. Panteleimon "- Plovdiv, Plovdiv, Bulgaria\|Multiprofile Hospital for Active Treatment Sveti Ivan Rilski - Razgrad AD, Razgrad, Bulgaria\|"Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -, Ruse, Bulgaria\|UMHAT Medica Ruse OOD, Ruse, Bulgaria\|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria\|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria\|Multiprofile Hospital For Active Treatment Shumen AD, Shumen, Bulgaria\|Multiprofile hospital for active treatment - Sliven to Military Medical Academy, Sliven, Bulgaria\|MHAT "Dr. Ivan Seliminski" AD, Sliven, Sliven, Bulgaria\|Diagnostic-Consultative Center XXII- Sofia ЕООD, Sofia, Bulgaria\|University First MHAT "St. Yoan Krastitel"-Sofia EAD, Sofia, Bulgaria\|UMHATEM N. I. Pirogov EAD, Sofia, Bulgaria\|MHAT "St. Sofia" EOOD, Sofia, Bulgaria\|Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD, Stara Zagora, Bulgaria\|Multiprofile Hospital for Active Treatment Targovishte AD, Targovishte, Bulgaria\|Outpatient Clinic for Primary Outpatient Medical Care "Puls" - Dr. Mladen Buchvarov EOOD, Tsarevo, Bulgaria\|Medical center Leo Clinic EOOD, Varna, Bulgaria\|MOBAL "D-r Stefan Cherkezov" AD, Veliko Tarnovo, Bulgaria\|Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD, Vratsa, Bulgaria\|Fundacion Centro de Investigacion Clinica CIC, Medellin, Antioquia, Colombia\|Centro Cardivascular Colombiano-Clinica Santa Maria, Medellin, Antioquia, Colombia\|Clinica de la Costa LTDA., Barranquilla, Atlantico, Colombia\|Hospital Universidad Del Norte, Soledad, Atlantico, Colombia\|IPS Medicos Internistas de Caldas, Manizales, Caldas, Colombia\|Caimed S.A.S., Yopal, Casanare, Colombia\|Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S, Bogota, Cundinamarca, Colombia\|Bluecare Salud S A S, Bogota, D.C, Colombia\|Fundacion Cardiomet CEQUIN, Armenia, Quindio, Colombia\|Instituto de investigaciones Centro Medico Imbanaco, Cali, Valle DEL Cauca, Colombia\|Doktor Brno s.r.o., Brno, Czechia\|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia\|MEDITRIAL s.r.o., Jindrichuv Hradec III, Czechia\|Zdraví-Fit, s.r.o., Protivín, Czechia\|Nemocnice Slany, Slany, Czechia\|Trial Pharma Kft., Bekescsaba, Hungary\|Semmelweis University Varosmajori Sziv Es Ergyogyaszati Klinika, Budapest, Hungary\|Varosmajori Sziv- es Ergyogyaszati Klinika, Budapest, Hungary\|Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika, Debrecen, Hungary\|Agria-Study Kft., Eger, Hungary\|Trial Pharma Kft., Gyula, Hungary\|Medifarma-98 Kft., Nyiregyhaza, Hungary\|International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan\|Rakuwakai Otowa Hospital, Kyoto-shi, Kyoto, Japan\|Rinku General Medical Center, Izumisano, Osaka, Japan\|Denenchofu Family Clinic, Ota, Tokyo, Japan\|Tokyo Shinagawa Hospital, Shinagawa-ku, Tokyo, Japan\|Sekino Hospital, Toshimaku, Tokyo, Japan\|Kyushu Medical Center, Fukuoka, Japan\|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of\|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia\|Klinik Kesihatan Greentown, Ipoh, Perak, Malaysia\|Hospital Seberang Jaya, Seberang Jaya, Pulau Pinang, Malaysia\|Hospital Miri, Miri, Sarawak, Malaysia\|Klinik Kesihatan Kuang, Sungai Buloh, Selangor, Malaysia\|InfectoLab Consultorios de Especialidad en Infectologia, Tijuana, BAJA California, Mexico\|Clinical Research Institute Saltillo S.A. de C.V., Saltillo, Coahuila, Mexico\|Centro de Investigacion Clinica Del Pacifico SA de CV, Acapulco de Juarez, Guerrero, Mexico\|Asociacion Mexicana para la Investigacion Clinica, A. C., Pachuca de Soto, Hidalgo, Mexico\|Instituto Jalisciense de Metabolismo, S.C., Guadalajara, Jalisco, Mexico\|JM Research, Cuernavaca, Morelos, Mexico\|Centro Médico Jojutla (Hospital Regional Jojutla)., Jojutla, Morelos, Mexico\|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico\|Eukarya Pharmasite S.C., Monterrey, Nuevo LEON, Mexico\|Christus- Latam Hub Center of Excellence and Innovation Center S.C., Monterrey, Nuevo LEÓN, Mexico\|Oaxaca site management organization s.c, Oaxaca de Juarez, Oaxaca, Mexico\|Hospital General de Culiacán "Bernardo J. Gastélum", Culíacan, Sinaloa, Mexico\|Kohler & Milstein Research S.A. de C.V., Merida, Yucatan, Mexico\|Eme Red Hospitalaria, Mérida, Yucatán, Mexico\|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico\|Instituto de Investigaciones Clínicas para la Salud, Durango, Mexico\|FAICIC Clinical Research, Veracruz, Mexico\|Sociedad de Metabolismo y Corazon S.C., Veracruz, Mexico\|Arke SMO S.A. de C.V, Veracruz, Mexico\|KLIMED Marek Klimkiewicz, Bialystok, Poland\|Krakowskie Centrum Medyczne, Krakow, Poland\|Przychodnia Valeo Medical, Lodz, Poland\|IRMED Ośrodek Badań Klinicznych, Piotrkow Trybunalski, Poland\|Tomasz Blicharski Lubelskie Centrum Diagnostyczne, Swidnik, Poland\|WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland\|Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska, Wroclaw, Poland\|Ponce Medical School Foundation, Inc. CAIMED Center, Ponce, Puerto Rico\|Clinical Research Management Group Inc, Ponce, Puerto Rico\|Advance Medical Research Center, San Juan, Puerto Rico\|Kirovsk Interdistrict Hospital, Kirovsk, Leningrad Region, Russian Federation\|LLC Trekhgorka Medicine, Odintsovo, Moscow Region, Russian Federation\|Private Medical Institution "Euromedservice", Pushkin, Saint-petersburg, Russian Federation\|Clinica UZI 4D, Pyatigorsk, Stavropol Region, Russian Federation\|Barnaul City Hospital Number 5, Barnaul, Russian Federation\|Korolev Medicine, Korolev, Russian Federation\|KDC "Evromedservis", OJSC, Moscow, Russian Federation\|City Polyclinic #44, Saint Petersburg, Russian Federation\|LLC Strategic Medical Systems, Saint Petersburg, Russian Federation\|Medical Research Institute, LLC, Saint Petersburg, Russian Federation\|City Polyclinic No. 109, Saint-Petersburg, Russian Federation\|Limited Liability Company "Center for Diagnostics and Rehabilitation "Praximed", Saint-Petersburg, Russian Federation\|City Out-patient clinic #112, Saint-Petersburg, Russian Federation\|"Research Center Eco-safety" LLC, Saint-Petersburg, Russian Federation\|LLC Kurator, Saint-Petersburg, Russian Federation\|Saint-Petersburg State Budgetary Healthcare Institution "City Pokrovskaya hospital", Saint-Petersburg, Russian Federation\|Astarta LLC, Saint-Petersburg, Russian Federation\|City Out-patient clinic #4, Saint-Petersburg, Russian Federation\|Smolensk State Medical University, Smolensk, Russian Federation\|LLC Family clinic, Yekaterinburg, Russian Federation\|Global Clinical Trials, Gqeberha, Eastern CAPE, South Africa\|Nelson Mandela Academic Clinical Research Unit (NeMACRU), Mthatha, Eastern CAPE, South Africa\|MERC Welkom, Welkom, FREE State, South Africa\|Worthwhile Clinical Trials, Benoni, Gauteng, South Africa\|REIMED Vosloorus, Boksburg, Gauteng, South Africa\|Lenasia Clinical Trial Centre, Johannesburg, Gauteng, South Africa\|LCS Clinical Research, Johannesburg, Gauteng, South Africa\|Peermed CTC (Pty) Ltd T/A MERC Kempton, Kempton Park, Gauteng, South Africa\|Midrand Medical Centre, Midrand, Gauteng, South Africa\|About Allergy (PTY) Ltd, Pretoria North, Gauteng, South Africa\|Global Clinical Trials, Pretoria, Gauteng, South Africa\|Botho ke Bontle Health Services, Pretoria, Gauteng, South Africa\|Emmed Research, Pretoria, Gauteng, South Africa\|Into Research, Pretoria, Gauteng, South Africa\|Clinical Trial Systems (Pty) Ltd, Pretoria, Gauteng, South Africa\|Sandton Medical Clinic, Sandton, Gauteng, South Africa\|FCRN Clinical Trial Centre, Vereeniging, Gauteng, South Africa\|Dr PJ Sebastian Clinical Research Centre, Durban, Kwa-zulu Natal, South Africa\|Synapta Clinical Research Center, Durban, Kwazulu Natal, South Africa\|Ahmed Al-Kadi Private Hospital, Mayville, Durban, Kwazulu-natal, South Africa\|Private Practice - Dr. Jeevren Reddy, Stanger, Kwazulu-natal, South Africa\|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa\|NHC Thohoyandou CRS, Thohoyandou, Limpopo, South Africa\|MERC Middelburg, Middelburg, Mpumalanga, South Africa\|Madibeng Centre for Research, Brits, North WEST, South Africa\|TASK Applied Science, Cape Town, Western CAPE, South Africa\|Red Zone Clinic, Cape Town, Western CAPE, South Africa\|Tiervlei Trial Centre, Cape Town, Western CAPE, South Africa\|TASK Eden, George, Western CAPE, South Africa\|Be Part Research Pty (Ltd), Paarl, Western CAPE, South Africa\|Clinical Projects Research, Worcester, Western CAPE, South Africa\|Synopsis Research, Claremont, South Africa\|Dr JM Engelbrecht Trial Site, Somerset West, South Africa\|Eba Centelles, Centelles, Barcelona [barcelona], Spain\|CAP Vicenç Papaceit, La Roca del Valles, Barcelona, Spain\|CAP La Mina, Sant Adria de Besos, Barcelona, Spain\|Hospital Universitario Mutua de Terrassa, Terrassa, Barcelona, Spain\|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain\|IMED Valencia, Burjassot, Valencia, Spain\|Complexo Hospitalario Universitario da Coruna, A Coruña, Spain\|Hospital Universitario Virgen de las Nieves, Granada, Spain\|Hospital Universitario de la Paz, Madrid, Spain\|Hospital Universitario Virgen de Valme, Sevilla, Spain\|Far Eastern Memorial Hospital, New Taipei City, Taiwan\|China Medical University Hospital, Taichung, Taiwan\|Taichung Veterans General Hospital, Taichung, Taiwan\|National Taiwan University Hospital, Taipei, Taiwan\|National Taiwan University Hospital, Taipei, Taiwan\|Bangkok Centre Hotel, Bangrak, Bangkok, Thailand\|Chula Filed hospital, Chulalongkorn University Sport center (Chantanayingyong Gymnasium),, Pathum Wan District,, Bangkok, Thailand\|Thai Red Cross Emerging Infectious Diseases (EDI) Clinic, Pathumwan,, Bangkok, Thailand\|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),, Pathumwan, Bangkok, Thailand\|Faculty of Medicine - Khon Kaen University, Muang, Khon Kaen, Thailand\|Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,, Hat Yai, Songkhla, Thailand\|King Chulalongkorn Memorial Hospital, Bangkok, Thailand\|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand\|Tropical Medicine Hospital, Bangkok, Thailand\|Cukurova University Medical Faculty, Balcali, Adana, Turkey\|Ankara University Medical Faculty, Ibni-Sina Hospital, Ankara, Turkey\|Hacettepe University Medical Faculty Hospital, Ankara, Turkey\|Akdeniz Universitesi Hastanesi, Antalya, Turkey\|Istanbul University Istanbul Medical Faculty, Fatih / Istanbul, Turkey\|Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi, Gaziantep, Turkey\|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey\|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Istanbul, Turkey\|Medipol Mega University Hospital, Istanbul, Turkey\|Acibadem University Atakent Hospital, Istanbul, Turkey\|Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, Turkey\|Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital, Izmir, Turkey\|Kocaeli University Medical Faculty, Kocaeli, Turkey\|Mersin University Medical Faculty, Mersin, Turkey\|Sakarya University Training and Research Hospital, Sakarya, Turkey\|Karadeniz Teknik Universitesi Farabi Hastanesi, Trabzon, Turkey\|Communal Medical Enterprise "Likarnya Prydniprovska", Kremenchuk, Poltava Region, Ukraine\|Regional Communal Nonprofit Institution "Chernivtsi Regional Clinical Hospital", Chernivtsi, Ukraine\|Communal non-commercial Enterprise "City Central Clinical Hospital" of Chernivtsi City Council, Chernivtsi, Ukraine\|Communal non-profit enterprise "City Clinical Hospital #16" of Dnipro City Council, Dnipro, Ukraine\|Municipal Nonprofit Enterprise "Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital of, Ivano-Frankivsk, Ukraine\|Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council", Ivano-Frankivsk, Ukraine\|Municipal Non-profit Enterprise "Ivano-Frankivsk Regional Phthisiopulmonology Center of, Ivano-Frankivsk, Ukraine\|Municipal Nonprofit Enterprise "City Student Hospital" of Kharkiv City Council, Kharkiv, Ukraine\|Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases, Kharkiv, Ukraine\|Municipal Nonprofit Enterprise "City Clinic Hospital # 13" of Kharkiv City Council, Kharkiv, Ukraine\|Municipal non-commercial enterprise "Kyiv City Clinical Hospital #1" Of Executive Body Of the Kyiv, Kyiv, Ukraine\|Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company, Kyiv, Ukraine\|Municipal non-profit enterprise of Lviv regional council "Lviv regional phthisiopulmonology clinical, Lviv, Ukraine\|Municipal NonProfit Enterprise of the Lviv Regional Council Lviv Regional Information and Analytical, Lviv, Ukraine\|Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4", Lviv, Ukraine\|Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional, Poltava, Ukraine\|University Hospital of Sumy State University, Sumy, Ukraine\|Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council, Tarasove Village, Ukraine\|Medical Center of Private Enterprise "Medical center INTERSONO", Uzhhorod, Ukraine\|Municipal Non-commercial Enterprise "Vinnytsia City Clinical Hospital №1", Vinnytsia, Ukraine\|Communal Enterprise "Hospital #1" of Zhytomyr City Council, Zhytomyr, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 2880 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of participants who have a negative reverse transcription polymerase chain reaction (RT-PCR) result at baseline who develop a symptomatic, RT-PCR or rapid antigen test confirmed SARS-CoV-2 infection.\|Percentage of participants who experience adverse events\|Efficacy in preventing symptomatic COVID-19 in participants who have a negative RT-PCR result at baseline and are at increased risk of severe COVID-19 illness\|Prevention of SARS CoV-2 infection in participants by RT-PCR status at enrolment\|Prevention of SARS CoV-2 infection in participants who have a negative RT-PCR result at baseline\|Compare the duration of COVID-19 related signs and symptoms in participants who have a negative RT-PCR result at baseline\|Compare the severity of COVID-19 related signs and symptoms in participants who have a negative RT-PCR result at baseline\|Minimal Concentration (Ctrough) of PF-07321332\|All cause mortality in participants who have a negative RT-PCR result at baseline\|Viral titers measured via RT-PCR in nasal swabs in participants who have a negative or positive RT-PCR result at baseline\|Number of days of hospital and intensive care unit stay in participants with COVID-19 related hospitalization who have a negative RT-PCR result at baseline\|Number of COVID-19 related medical visits in participants who have a negative RT-PCR result at baseline
NCT02735707	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	Recruiting	Phase 3	Apr/11/2016	Dec/01/2025
Alternative id - U1111-1189-1653\|2015-002340-14\|602525\|16/631\|APP1101719\|158584 Interventions - Drug: Ceftriaxone\|Drug: Moxifloxacin or Levofloxacin\|Drug: Piperacillin-tazobactam\|Drug: Ceftaroline\|Drug: Amoxicillin-clavulanate\|Drug: Standard course macrolide\|Drug: Extended course macrolide\|Other: No systemic corticosteroid\|Drug: Fixed-duration Hydrocortisone\|Drug: Shock-dependent hydrocortisone\|Drug: Fixed-duration higher dose Hydrocortisone\|Other: No antiviral agent for influenza\|Drug: Five-days oseltamivir\|Drug: Ten-days oseltamivir\|Other: No antiviral agent for COVID-19\|Drug: Lopinavir / Ritonavir\|Drug: Hydroxychloroquine\|Drug: Hydroxychloroquine + lopinavir/ritonavir\|Drug: Ivermectin\|Other: No immune modulation for COVID-19\|Drug: Interferon beta-1a\|Drug: Anakinra\|Drug: Tocilizumab\|Drug: Sarilumab\|Drug: Local standard venous thromboprophylaxis\|Drug: Therapeutic anticoagulation\|Drug: Conventional low dose thromboprophylaxis\|Drug: Intermediate dose thromboprophylaxis\|Drug: Continuation of therapeutic dose anticoagulation\|Other: No immunoglobulin\|Biological: Convalescent plasma\|Biological: Delayed administration of convalescent plasma\|Other: No vitamin C\|Drug: Vitamin C\|Other: No antiplatelet\|Drug: Aspirin\|Drug: P2Y12 inhibitor\|Other: No simvastatin\|Drug: Simvastatin\|Other: Placebo\|Drug: Eritoran\|Drug: Apremilast\|Procedure: Clinician-preferred mechanical ventilation strategy\|Procedure: Protocolised mechanical ventilation strategy\|Other: No renin-angiotensin system inhibitor\|Drug: Angiotensin converting enzyme inhibitor\|Drug: Angiotensin Receptor Blockers\|Drug: ARB + DMX-200\|Other: No cysteamine\|Drug: Cysteamine Study type - Interventional Study results - No Results Available Locations - University of Florida, Jacksonville, Florida, United States\|Augusta University, Augusta, Georgia, United States\|University of Illinois Health, Chicago, Illinois, United States\|Tulane Medical Center, New Orleans, Louisiana, United States\|University of Michigan, Ann Arbor, Michigan, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, United States\|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States\|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States\|Oregon Health and Science University, Portland, Oregon, United States\|University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States\|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States\|Canberra Hospital, Canberra, Australian Capital Territory, Australia\|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia\|Blacktown Hospital, Blacktown, New South Wales, Australia\|Campbelltown Hospital, Campbelltown, New South Wales, Australia\|Sutherland Hospital, Caringbah, New South Wales, Australia\|Concord Hospital, Concord, New South Wales, Australia\|Dubbo Base Hospital, Dubbo, New South Wales, Australia\|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia\|Nepean Hospital, Kingswood, New South Wales, Australia\|St. George Hospital, Kogarah, New South Wales, Australia\|Liverpool Hospital, Liverpool, New South Wales, Australia\|John Hunter Hospital, Newcastle, New South Wales, Australia\|Orange Health Service, Orange, New South Wales, Australia\|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia\|Prince of Wales Hospital, Sydney, New South Wales, Australia\|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia\|Royal North Shore Hospital, Sydney, New South Wales, Australia\|Wollongong Hospital, Sydney, New South Wales, Australia\|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia\|Westmead Hospital, Westmead, New South Wales, Australia\|Royal Darwin Hospital,, Darwin, Northern Territory, Australia\|Sunshine Coast University Hospital, Birtinya, Queensland, Australia\|The Prince Charles Hospital, Brisbane, Queensland, Australia\|Mater Hospital Brisbane, Brisbane, Queensland, Australia\|Princess Alexandra Hospital, Brisbane, Queensland, Australia\|Caboolture Hospital, Caboolture, Queensland, Australia\|Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia\|Logan Hospital, Logan, Queensland, Australia\|Redcliffe Hospital, Redcliffe, Queensland, Australia\|Rockhampton Hospital, Rockhampton, Queensland, Australia\|Gold Coast University Hospital, Southport, Queensland, Australia\|Toowoomba Hospital, Toowoomba, Queensland, Australia\|Townsville Hospital, Townsville, Queensland, Australia\|Royal Adelaide Hospital, Adelaide, South Australia, Australia\|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia\|Lyell McEwin Hospital, Adelaide, South Australia, Australia\|Flinders Medical Centre, Bedford Park, South Australia, Australia\|Launceston Hospital, Launceston, Tasmania, Australia\|Ballarat Base Hospital, Ballarat, Victoria, Australia\|Bendigo Hospital, Bendigo, Victoria, Australia\|Casey Hospital, Berwick, Victoria, Australia\|Box Hill Hospital, Box Hill, Victoria, Australia\|Monash Medical Centre, Clayton, Victoria, Australia\|Dandenong Hospital, Dandenong, Victoria, Australia\|Angliss Hospital, Ferntree Gully, Victoria, Australia\|Footscray Hospital, Footscray, Victoria, Australia\|University Hosptial Geelong, Geelong, Victoria, Australia\|The Alfred Hospital, Melbourne, Victoria, Australia\|Royal Melbourne Hospital, Melbourne, Victoria, Australia\|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia\|Maroondah Hospital, Ringwood East, Victoria, Australia\|Sunshine Hospital, Sunshine, Victoria, Australia\|Werribee Mercy Hospital, Werribee, Victoria, Australia\|St John of God Hospital Midland, Midland, Western Australia, Australia\|St John of God Hospital Murdoch, Murdoch, Western Australia, Australia\|Royal Perth Hospital, Perth, Western Australia, Australia\|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia\|Fiona Stanley Hospital, Perth, Western Australia, Australia\|St John of God Subiaco, Subiaco, Western Australia, Australia\|AZ Sint-Jan, Brugge, Belgium\|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium\|Universitair Ziekenhuis Antwerp, Edegem, Belgium\|Universitair Ziekenhuis Gent, Gent, Belgium\|Foothills Medical Centre, Calgary, Alberta, Canada\|Peter Lougheed Centre, Calgary, Alberta, Canada\|Rockyview General Hospital, Calgary, Alberta, Canada\|South Health Campus, Calgary, Alberta, Canada\|Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada\|University of Alberta Hospital, Edmonton, Alberta, Canada\|Surrey Memorial Hospital, Surrey, British Columbia, Canada\|St Boniface General Hospital, Winnipeg, Manitoba, Canada\|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada\|Grace Hospital, Winnipeg, Manitoba, Canada\|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada\|The Moncton Hospital, Fredericton, New Brunswick, Canada\|The Saint John General Hospital, Fredericton, New Brunswick, Canada\|William Osler Health System, Brampton, Ontario, Canada\|Brantford General Hospital, Brantford, Ontario, Canada\|Hamilton general Hospital, Hamilton, Ontario, Canada\|Juravinski Hospital, Hamilton, Ontario, Canada\|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada\|Kingston Health Sciences Centre, Kingston, Ontario, Canada\|Grand River Hospital, Kitchener, Ontario, Canada\|St Mary's General Hospital, Kitchener, Ontario, Canada\|The Ottawa Hospital, Ottawa, Ontario, Canada\|Niagara Health, Saint Catharines, Ontario, Canada\|Thunder Bay General Hospital, Thunder Bay, Ontario, Canada\|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada\|St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada\|Mount Sinai Hospital, Toronto, Ontario, Canada\|Toronto General Hospital, Toronto, Ontario, Canada\|Toronto Western Hospital, Toronto, Ontario, Canada\|St Joseph's Health Centre, Toronto, Ontario, Canada\|CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada\|Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada\|Hôpital Fleury, Montréal, Quebec, Canada\|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada\|McGill University Health Centre, Montréal, Quebec, Canada\|Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada\|CHU de Québec - Université Laval, Québec, Quebec, Canada\|IUCPQ-UL, Québec, Quebec, Canada\|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada\|Regina General Hospital, Saskatoon, Saskatchewan, Canada\|Universidad de La Sabana, Chía, Cundinamarca, Colombia\|General County Hospital Požega, Požega, Croatia\|University Hospital Centre Zagreb, Zagreb, Croatia\|University Hospital for Infectious Diseases, Zagreb, Croatia\|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany\|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany\|Vivantes Klinikum Neukölln, Berlin, Germany\|Universitätsklinikum Köln, Cologne, Germany\|Universitätsklinikum Frankfurt, Frankfurt, Germany\|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany\|Medizinische Hochschule Hannover, Hannover, Germany\|Universitätsklinikum Jena, Jena, Germany\|Universitätsklinikum Leipzig, Leipzig, Germany\|Universitäts Klinikum Tübingen, Tübingen, Germany\|Universitätsklinikum Würzburg, Würzburg, Germany\|Jósa András County Hospital, Nyíregyháza, Hungary\|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary\|Almási Balogh Pál Kórház, Ózd, Hungary\|Apollo Main Hospital, Chennai, Tamil Nadu, India\|Apollo First Med Hospital, Chennai, Tamil Nadu, India\|Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India\|Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India\|Beaumont Hospital, Dublin, Ireland\|St. Vincent's University Hospital, Dublin, Ireland\|University Hospital Galway, Galway, Ireland\|St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan\|Yokohama City University Hospital, Yokohama, Kanagawa, Japan\|St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan\|Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan\|Osaka City General Hospital, Osaka, Japan\|Nerima Hikarigaoka Hospital, Tokyo, Japan\|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan\|Itabashi Chuo Medical Center, Tokyo, Japan\|Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan\|Wakayama Medical University, Wakayama, Japan\|Chitwan Medical College, Bharatpur, Nepal\|Grande International Hospital, Kathmandu, Nepal\|Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal\|Nepal Mediciti, Kathmandu, Nepal\|Meander Medisch Centrum, Amersfoort, Netherlands\|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands\|Martini Hospital Groningen, Groningen, Netherlands\|University Medical Center Groningen, Groningen, Netherlands\|Leiden University Medical Center, Leiden, Netherlands\|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands\|Radboud University Medical Center, Nijmegen, Netherlands\|University Medical Center Utrecht, Utrecht, Netherlands\|North Shore Hospital, Auckland, New Zealand\|CVICU, Auckland City Hospital, Auckland, New Zealand\|DCCM, Auckland City Hospital, Auckland, New Zealand\|Middlemore Hospital, Auckland, New Zealand\|Christchurch Hospital, Christchurch, New Zealand\|Waikato Hospital, Hamilton, New Zealand\|Taranaki Base Hospital, New Plymouth, New Zealand\|Rotorua Hospital, Rotorua, New Zealand\|Tauranga Hospital, Tauranga, New Zealand\|Wellington Regional Hospital, Wellington, New Zealand\|Whangarei Hospital, Whangarei, New Zealand\|Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan\|Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan\|National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan\|South City Hospital, Karachi, Karachi, Sindh, Pakistan\|Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan\|Centro Hospitalar do Medio Tejo, Abrantes, Portugal\|Hospital Lusíadas Lisbon, Lisboa, Portugal\|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania\|King Abdulaziz Medical City, Riyadh, Saudi Arabia\|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain\|Hospital Universitario Reina Sofia, Córdoba, Spain\|Basildon Hospital, Basildon, England, United Kingdom\|Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom\|Royal United Hospital, Bath, Bath, England, United Kingdom\|Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom\|Birmingham City Hospital, Birmingham, England, United Kingdom\|Blackburn Hospital, Blackburn, England, United Kingdom\|Pilgrim's Hospital, Boston, England, United Kingdom\|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom\|Royal Sussex County Hospital, Brighton, England, United Kingdom\|Southmead Hospital, Bristol, England, United Kingdom\|Bristol Royal Hospital, Bristol, England, United Kingdom\|Queen's Hospital, Burton, Burton on Trent, England, United Kingdom\|Royal Papworth Hospital, Cambridge, England, United Kingdom\|Addenbrookes Hospital, Cambridge, England, United Kingdom\|Cumberland Royal Infirmary, Carlisle, England, United Kingdom\|Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom\|Chesterfield Royal Hospital, Chesterfield, England, United Kingdom\|Countess of Chester Hospital, Chester, England, United Kingdom\|Colchester Hospital, Colchester, England, United Kingdom\|University Hospital Coventry, Coventry, England, United Kingdom\|North Manchester General Hospital, Crumpsall, England, United Kingdom\|Darlington Memorial Hospital, Darlington, England, United Kingdom\|Darent Valley Hospital, Dartford, England, United Kingdom\|Russells Hall Hospital, Dudley, England, United Kingdom\|University Hospital of North Durham, Durham, England, United Kingdom\|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom\|Frimley Park Hospital, Frimley, England, United Kingdom\|Queen Elizabeth Hospital, Gateshead, England, United Kingdom\|Medway Maritime Hospital, Gillingham, England, United Kingdom\|James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom\|Royal Surrey County Hospital, Guildford, England, United Kingdom\|Northwick Park Hospital, Harrow, England, United Kingdom\|Hereford County Hospital, Hereford, England, United Kingdom\|Barnet Hospital, High Barnet, England, United Kingdom\|Huddersfield Hospital, Huddersfield, England, United Kingdom\|King George Hospital, Ilford, England, United Kingdom\|Ipswich Hospital, Ipswich, England, United Kingdom\|Kettering Hospital, Kettering, England, United Kingdom\|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom\|Leicester Royal Infirmary, Leicester, England, United Kingdom\|Glenfield Hospital, Leicester, England, United Kingdom\|Lincoln County Hospital, Lincoln, England, United Kingdom\|Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom\|Alder Hey Hospital, Liverpool, England, United Kingdom\|Royal Liverpool Hospital, Liverpool, England, United Kingdom\|University Hospital Aintree, Liverpool, England, United Kingdom\|Croydon University Hospital, London, England, United Kingdom\|Royal London Hospital, London, England, United Kingdom\|Whipps Cross Hospital, London, England, United Kingdom\|Newham Hospital, London, England, United Kingdom\|St Barts Hosptial, London, England, United Kingdom\|North Middlesex Hospital, London, England, United Kingdom\|Royal Free Hospital, London, England, United Kingdom\|St Thomas' Hospital, London, England, United Kingdom\|Guy's Hospital, London, England, United Kingdom\|King's College Hospital, London, England, United Kingdom\|St George's Hospital, London, England, United Kingdom\|Royal Marsden Hospital, London, England, United Kingdom\|Ryal Brompton, London, England, United Kingdom\|Hammersmith Hospital, London, England, United Kingdom\|St Mary's Hospital, London, England, United Kingdom\|Charing Cross Hospital, London, England, United Kingdom\|Luton and Dunstable University Hospital, Luton, England, United Kingdom\|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom\|Manchester Royal Infirmary, Manchester, England, United Kingdom\|The Christie Hospital, Manchester, England, United Kingdom\|Wythenshawe Hospital, Manchester, England, United Kingdom\|Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom\|The James Cook University Hospital, Middlesbrough, England, United Kingdom\|Milton Keynes University Hospital, Milton Keynes, England, United Kingdom\|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom\|Newcastle Freeman Hospital, Newcastle, England, United Kingdom\|Northampton General Hospital, Northampton, England, United Kingdom\|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom\|City Hospital Nottingham, Nottingham, England, United Kingdom\|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom\|George Eliot Hospital, Nuneaton, England, United Kingdom\|Royal Oldham Hospital, Oldham, England, United Kingdom\|Princess Royal University Hospital, Orpington, England, United Kingdom\|John Radcliffe Hospital, Oxford, England, United Kingdom\|Derriford Hospital, Plymouth, England, United Kingdom\|Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom\|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom\|Whiston Hospital, Prescot, England, United Kingdom\|Royal Preston Hospital, Preston, England, United Kingdom\|Royal Berkshire Hospital, Reading, England, United Kingdom\|Alexandra Hospital, Redditch, Redditch, England, United Kingdom\|Queen's Hospital Romford, Romford, England, United Kingdom\|Rotherham General Hospital, Rotherham, England, United Kingdom\|Salford Royal Hospital, Salford, England, United Kingdom\|Salisbury District Hospital, Salisbury, England, United Kingdom\|Royal Hallamshire Hospital, Sheffield, England, United Kingdom\|Northern General Hospital, Sheffield, England, United Kingdom\|Wexham Park Hospital, Slough, England, United Kingdom\|South Tyneside District Hospital, South Shields, England, United Kingdom\|Southampton General Hospital, Southampton, England, United Kingdom\|Stepping Hill Hospital, Stockport, England, United Kingdom\|University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom\|Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom\|Sunderland Hospital, Sunderland, England, United Kingdom\|King's Mill Hospital, Sutton In Ashfield, England, United Kingdom\|Great Western Hospital, Swindon, England, United Kingdom\|Western General Hospital, Swindon, England, United Kingdom\|Musgrove Park Hospital, Taunton, England, United Kingdom\|Torbay and South Devon Hospital, Torquay, England, United Kingdom\|Royal Cornwall Hospital, Truro, England, United Kingdom\|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom\|Harefield Hospital, Uxbridge, England, United Kingdom\|Watford General Hospital, Watford, England, United Kingdom\|Southend University Hospital, Westcliff-on-Sea, England, United Kingdom\|West Cumberland Hospital, Whitehaven, England, United Kingdom\|Royal Albert Edward Infirmary, Wigan, England, United Kingdom\|Royal Hampshire Hospital, Winchester, England, United Kingdom\|Arrow Park Hospital, Wirral, England, United Kingdom\|New Cross Hospital, Wolverhampton, England, United Kingdom\|Worcester Royal Hospital, Worcester, England, United Kingdom\|York Hospital, York, England, United Kingdom\|York Hospital, York, England, United Kingdom\|Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom\|Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom\|Mater Hospital, Belfast, Northern Ireland, United Kingdom\|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom\|Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom\|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom\|Ninewells Hospital, Dundee, Scotland, United Kingdom\|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom\|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom\|Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom\|Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom\|Neville Hall Hospital, Abergavenny, Wales, United Kingdom\|Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom\|Princess of Wales Hospital, Bridgend, Wales, United Kingdom\|University Hospital of Wales, Cardiff, Wales, United Kingdom\|Glangwilli Hospital, Carmarthen, Wales, United Kingdom\|Grange University Hospital, Cwmbran, Wales, United Kingdom\|Royal Gwent Hospital, Newport, Wales, United Kingdom\|Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom\|Morriston Hospital, Swansea, Wales, United Kingdom\|Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Days alive and not receiving organ support in ICU\|ICU Mortality\|ICU length of stay\|Hospital length of stay\|Ventilator free days\|Organ failure free days\|Health-related Quality of life assessment\|Proportion of intubated patients who receive a tracheostomy\|Destination at time of hospital discharge\|Readmission to the index ICU during the index hospitalization\|World Health Organisation 8-point ordinal scale outcome
NCT04738045	Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients	Recruiting	Phase 4	Nov/01/2020	Apr/01/2021
Alternative id - REC-H-PhBSU-21001 Interventions - Drug: Remdesivir\|Drug: Lopinavir/ Ritonavir and Remdesivir combination Study type - Interventional Study results - No Results Available Locations - Beni-suef University, Banī Suwayf, Egypt Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 90 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group\|Monitoring of adverse events.
NCT04521400	the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19	Not yet recruiting	Phase 2	Aug/20/2020	Sep/11/2020
Alternative id - Interferon in COVID Interventions - Drug: High dose Interferon-beta 1a\|Drug: Lopinavir/Ritonavir\|Drug: Low dose Interferon-beta 1a Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization\|Cumulative incidence of serious adverse events
NCT04351724	Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)	Recruiting	Phase 2\|Phase 3	Apr/16/2020	Mar/31/2022
Alternative id - ACOVACT Interventions - Drug: Chloroquine or Hydroxychloroquine\|Drug: Lopinavir/Ritonavir\|Other: Best standard of care\|Drug: Rivaroxaban\|Drug: Thromboprophylaxis\|Drug: Candesartan\|Drug: non-RAS blocking antihypertensives\|Drug: Remdesivir\|Drug: Asunercept 400mg\|Drug: Asunercept 100mg\|Drug: Asunercept 25mg\|Drug: Pentaglobin Study type - Interventional Study results - No Results Available Locations - Medical University of Innsbruck, Innsbruck, Tirol, Austria\|Medical University of Graz, Graz, Austria\|Kepler University Hospital, Linz, Austria\|Medical University of Vienna, Vienna, Austria\|Wilhelminenspital, Vienna, Austria\|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria\|KH Hietzing, Vienna, Austria\|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria\|SMZ Ost Donauspital, Vienna, Austria Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 500 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - sustained improvement (>48h) of one point on the WHO Scale\|Time to improvement on WHO Scale\|Mean change in the ranking on an ordinal scale from baseline\|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first\|change from baseline in National Early Warning Score (NEWS)\|Oxygenation free days\|Incidence of new oxygen use during the trial\|duration of oxygen use during the trial\|Ventilator free days until day 29\|Incidence of new mechanical ventilation use during the trial\|duration of mechanical ventilation use during the trial\|Viral load/viral clearance\|Duration of Hospitalization\|Mortality\|Obesity - mortality\|Obesity - duration of hospitalization\|Obesity - ICU admission\|Obesity - new oxygen use\|Drug-drug interactions with lopinavir/ritonavir\|Renin Angiotensin System (RAS) fingerprint\|SpO2/FiO2 ratio\|paO/FiO2 ratio\|modified Sequential Organ Failure Assessment\|C-reactive protein\|Interleukin-6\|procalcitonin\|IgM Concentrations\|IgA Concentrations\|differential blood counts
NCT04376814	Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19	Completed	Not Applicable	Mar/29/2020	May/25/2020
Alternative id - IR.BMSU.REC.1399.017 Interventions - Drug: Favipiravir\|Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir Study type - Interventional Study results - No Results Available Locations - Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 40 Age - 16 Years to 100 Years (Child, Adult, Older Adult) Outcome measures - Mortality\|long of hospitalization\|Laboratory Treatment Response (Blood cell count)\|Laboratory Treatment Response (CRP )\|Dyspnea\|Oxygen saturation without supplemental oxygen.\|Oxygen therapy
NCT04466241	Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial	Recruiting	Phase 2\|Phase 3	Nov/27/2020	Mar/26/2021
Alternative id - ANRS COV01 INTENSE COV Interventions - Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet\|Drug: Telmisartan 40Mg Oral Tablet\|Drug: Atorvastatin 20 Mg Oral Tablet Study type - Interventional Study results - No Results Available Locations - Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire\|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 294 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11\|Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28\|Kinetics of SARS-CoV-2 viral load\|Death rate at Day 11 and Day 28\|All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28\|Time to hospital discharge\|Duration of oxygen supplementation\|Prevalence of grade III or IV adverse events\|Residual concentration of lopinavir, telmisartan and atorvastatin\|Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes)\|Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2)\|Proportion of patients with good results according to HIV status\|Number of contact cases infected by COVID-19 at Day 28
NCT05011513	Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).	Active, not recruiting	Phase 2\|Phase 3	Aug/25/2021	Apr/25/2022
Alternative id - C4671002\|2021-002857-28\|EPIC-SR Interventions - Drug: PF-07321332\|Drug: Ritonavir\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Cahaba Research Inc, Birmingham, Alabama, United States\|Cahaba Research, Inc., Birmingham, Alabama, United States\|Cahaba Research, Inc., Pelham, Alabama, United States\|The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States\|The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States\|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States\|Hope Clinical Research, Canoga Park, California, United States\|Lightship, El Segundo, California, United States\|Ascada Research, Fullerton, California, United States\|eStudySite, La Mesa, California, United States\|Atella Clinical Research LLC., La Palma, California, United States\|Ark Clinical Research, Long Beach, California, United States\|American Institute of Research, Los Angeles, California, United States\|Providence Clinical Research, North Hollywood, California, United States\|FOMAT Medical Research, Oxnard, California, United States\|Stanford University, Palo Alto, California, United States\|Benchmark Research, Sacramento, California, United States\|Optimus Medical Group, San Francisco, California, United States\|South Bay Clinical Research Institute, Torrance, California, United States\|Hope Clinical Research (COVID Satellite Site), West Hills, California, United States\|Future Innovative Treatments, LLC, Colorado Springs, Colorado, United States\|BRB Health Group DBA Broward Research Center, Aventura, Florida, United States\|Xera Med Research, Boca Raton, Florida, United States\|Synergy Healthcare, Bradenton, Florida, United States\|MOORE Clinical Research, Inc., Brandon, Florida, United States\|Innovative Research of West Florida, Clearwater, Florida, United States\|Herco Medical and Research Center Inc, Coral Gables, Florida, United States\|Advance Clinical Research Group, Cutler Bay, Florida, United States\|Beautiful Minds Clinical Research Center, Cutler Bay, Florida, United States\|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States\|Unlimited Medical Research Group, LLC, Hialeah Gardens, Florida, United States\|Qway Research, LLC, Hialeah, Florida, United States\|Eastern Research Inc, Hialeah, Florida, United States\|Inpatient Research Clinic, Hialeah, Florida, United States\|Doral Medical Research, LLC, Hialeah, Florida, United States\|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States\|Asclepes Research Centers, Lutz, Florida, United States\|Pro-Care Research Center, Corp., Miami Gardens, Florida, United States\|Lakes Research, LLC., Miami Lakes, Florida, United States\|Savin Medical Group, LLC, Miami Lakes, Florida, United States\|Angels Clinical Research Institute, Miami, Florida, United States\|Nova Life Med Spa, Miami, Florida, United States\|LCC Medical Research Institute, LLC, Miami, Florida, United States\|Premium Medical Research Corp, Miami, Florida, United States\|Global Health Clinical Trials Corp, Miami, Florida, United States\|South Florida Research Center, Inc., Miami, Florida, United States\|Suncoast Research Group, LLC, Miami, Florida, United States\|University of Miami Health System, Miami, Florida, United States\|I.V.A.M. Clinical & Investigational Center, LLC, Miami, Florida, United States\|Entrust Clinical Research, Miami, Florida, United States\|Medical Research of Westchester Inc, Miami, Florida, United States\|C'A Research, Miami, Florida, United States\|ProLive Medical Research, Corp., Miami, Florida, United States\|Reed Medical Research, Miami, Florida, United States\|Kendall South Medical Center, Inc., Miami, Florida, United States\|Clinical Site Partners, Inc d/b/a CSP Miami, Miami, Florida, United States\|Coral Research Clinic Corp, Miami, Florida, United States\|Omega Research Orlando, LLC, Orlando, Florida, United States\|NAPA Research LLC, Pompano Beach, Florida, United States\|CDC Research Institute, Port Saint Lucie, Florida, United States\|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States\|Accel Research Sites - St. Petersburg Clinical Research Unit, Saint Petersburg, Florida, United States\|Professional Urgent Care Services, Saint Petersburg, Florida, United States\|USPA Advance Concept Medical Research Group LLC, South Miami, Florida, United States\|Asclepes Research Centers, Spring Hill, Florida, United States\|Sunrise Research Institute, Sunrise, Florida, United States\|Tampa General Hospital, Tampa, Florida, United States\|Santos Research Center, CORP, Tampa, Florida, United States\|Palm Beach Research Center, West Palm Beach, Florida, United States\|Clinical Site Partners, Inc. dba CSP Orlando, Winter Park, Florida, United States\|Emory Clinic Investigational Drug Services, Atlanta, Georgia, United States\|The Hope Clinic at Emory University - Annex, Decatur, Georgia, United States\|The Hope Clinic at Emory University, Decatur, Georgia, United States\|The Hope Clinic Investigational Drug Services - Satellite Pharmacy, Decatur, Georgia, United States\|The South Bend Clinic Center for Research, South Bend, Indiana, United States\|Accellacare, Ames, Iowa, United States\|McFarland Clinic, PC, Ames, Iowa, United States\|WKB Family Medicine Associates, Bossier City, Louisiana, United States\|New Orleans Sinus Center (COVID-19 Testing), Marrero, Louisiana, United States\|Tandem Clinical Research GI, LLC, Marrero, Louisiana, United States\|Southern Clinical Research Associates, LLC, Metairie, Louisiana, United States\|MedPharmics LLC, Metairie, Louisiana, United States\|Willis-Knighton Health System, Shreveport, Louisiana, United States\|Michigan Center of Medical Research, Farmington Hills, Michigan, United States\|Jackson Medical Mall, Jackson, Mississippi, United States\|Lakeland Pharmacy, Branson W., Missouri, United States\|CVS, Springfield, Missouri, United States\|Mercury Street Medical Group, PLLC, Butte, Montana, United States\|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States\|Quality Clinical Research Inc, Omaha, Nebraska, United States\|Quality Clinical Research, Omaha, Nebraska, United States\|Walmart, Las Vegas, Nevada, United States\|Excel Clinical Research, Las Vegas, Nevada, United States\|Walgreens, Las Vegas, Nevada, United States\|AXCES Research Group, Santa Fe, New Mexico, United States\|Meridian Clinical Research, LLC, Endwell, New York, United States\|NYC Health + Hospitals/Harlem, New York, New York, United States\|Monroe Biomedical Research, Monroe, North Carolina, United States\|Accellacare, Wilmington, North Carolina, United States\|Innovo Research: Wilmington Health, Wilmington, North Carolina, United States\|Rhode Island Hospital, Providence, Rhode Island, United States\|The Miriam Hospital, Providence, Rhode Island, United States\|Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, United States\|Avera Research Institute, Sioux Falls, South Dakota, United States\|Premier Medical Group, Clarksville, Tennessee, United States\|PharmaTex Research, LLC, Amarillo, Texas, United States\|ARC Clinical Research at William Cannon, Austin, Texas, United States\|St Hope Foundation, Bellaire, Texas, United States\|Conroe Willis Medical Research, Conroe, Texas, United States\|South Texas Clinical Research, Corpus Christi, Texas, United States\|Urgent Care Clinical Trials at City Doc McKinney, Dallas, Texas, United States\|SignatureCare Emergency Center, Houston, Texas, United States\|Trio Clinical Trials, LLC, Houston, Texas, United States\|C & R Research Services USA, Houston, Texas, United States\|Houston Methodist Hospital, Houston, Texas, United States\|Next Level Urgent Care, Houston, Texas, United States\|SMS Clinical Research, LLC, Mesquite, Texas, United States\|LinQ Research, LLC, Pearland, Texas, United States\|Epic Medical Research, Red Oak, Texas, United States\|Sun Research Institute, San Antonio, Texas, United States\|Endeavor Clinical Trials, LLC, San Antonio, Texas, United States\|BFHC Research, San Antonio, Texas, United States\|Tranquility Research, Webster, Texas, United States\|University of Utah Medical Center, Salt Lake City, Utah, United States\|TMPG Clinical Research, Newport News, Virginia, United States\|TPMG Clinical Research, Newport News, Virginia, United States\|Centro Médico Viamonte, Caba, Buenos Aires, Argentina\|DIM Clinica Privada, Ramos Mejia, Buenos Aires, Argentina\|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina\|Instituto Médico de la Fundación Estudios Clínicos (Fundación Estudios Clínicos), Rosario, Santa FE, Argentina\|Sanatorio Britanico S.A., Rosario, Santa FE, Argentina\|Instituto CAICI, Rosario, Santa FE, Argentina\|Hospital de Clinicas Presidente Nicolas Avellaneda, San Miguel de Tucuman, Tucuman, Argentina\|Clinica Mayo Urgencias Medicas Cruz Blanca SRL, San Miguel de Tucuman, Tucuman, Argentina\|Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina\|Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil\|Chronos Pesquisa Clinica, Brasilia, Distrito Federal, Brazil\|AMB3 Serviços Médicos Ltda, Cuiabá, MATO Grosso, Brazil\|Hospital Luxemburgo - Associacao Mario Penna, Belo Horizonte, MG, Brazil\|School of Medicine Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil\|Hospital Agamenon Magalhaes, Recife, Pernambuco, Brazil\|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, RIO Grande DO Norte, Brazil\|Hospital De Clinicas De Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil\|IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil\|Instituto Nacional de Infectologia Evandro Chagas - INI/FIOCRUZ, Rio de Janeiro, RJ, Brazil\|CECOR - Centro Oncológico de Roraima, Boa Vista, Roraima/rr, Brazil\|Hospital Regional Hans Dieter Schmidt (HRHDS), Joinville, Santa Catarina/sc, Brazil\|Scentryphar - Pesquisa ClInica, Campinas, SAO Paulo, Brazil\|Centro de Estudos Clinicos do Interior Paulista (CECIP), Jau, SAO Paulo, Brazil\|Hospital Dia do Pulmao, Blumenau, SC, Brazil\|Hospital e Maternidade Celso Pierro - PUC Campinas / Sociedade Campineira de Educação e Instruçã, Campinas, SP, Brazil\|Pesquisare Saude S/S Ltda, Santo André, SP, Brazil\|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil\|Unidade Referenciada Oswaldo Cruz Vergueiro, São Paulo, SP, Brazil\|Hospital Heliópolis, São Paulo, SP, Brazil\|Instituto D'Or de Pesquisa e Ensino / Hospital São Luiz Jabaquara, São Paulo, SP, Brazil\|Scentryphar - Pesquisa ClInica, Campinas, SÃO Paulo, Brazil\|Associação Evangélica de Campinas - Hospital Samaritano, Campinas, SÃO Paulo, Brazil\|Instituto de Pesquisa Clínica de Campinas, Campinas, SÃO Paulo, Brazil\|Centro de Referência e Treinamento DST/AIDS, Sao Paulo, SÃO Paulo, Brazil\|Clinica de Alergia Martti Antila, Sorocaba, SÃO Paulo, Brazil\|CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, SÃO Paulo, Brazil\|CPCLIN - Centro de Pesquisas Clinicas Ltda, São Paulo, Brazil\|Instituto de Infectologia Emilio Ribas, São Paulo, Brazil\|Conjunto Hospitalar do Mandaqui, São Paulo, Brazil\|Individual Practice for Primary Medical Care - IPPMC - Dr. P. Panayotov EOOD, Burgas, Bulgaria\|MHAT St. Ekaterina, Dimitrovgrad EOOD, Dimitrovgrad, Bulgaria\|"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd, Haskovo, Bulgaria\|MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD, Kozloduy, Bulgaria\|Diagnostic-Consultative Center I Lom EOOD, Lom, Bulgaria\|Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD, Lom, Bulgaria\|Medical centre Leo Clinic EOOD, Lovech, Bulgaria\|MHAT Heart and Brain EAD, Pleven, Bulgaria\|UMHAT Sveta Marina - Pleven, Pleven, Bulgaria\|DCC Sveti Georgi EOOD, Plovdiv, Bulgaria\|MHAT "St. Panteleimon "- Plovdiv, Plovdiv, Bulgaria\|Multi-Profile Hospital for Active treatment ''Plovdiv''AD, Plovdiv, Bulgaria\|Multiprofile Hospital for Active Treatment Sveti Ivan Rilski - Razgrad AD, Razgrad, Bulgaria\|"Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -, Ruse, Bulgaria\|UMHAT Medica Ruse OOD, Ruse, Bulgaria\|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria\|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria\|Multiprofile Hospital For Active Treatment Shumen AD, Shumen, Bulgaria\|Multiprofile hospital for active treatment - Sliven to Military Medical Academy, Sliven, Bulgaria\|MHAT "Dr. Ivan Seliminski" AD, Sliven, Sliven, Bulgaria\|Diagnostic-Consultative Center XXII- Sofia ЕООD, Sofia, Bulgaria\|University First MHAT "St. Yoan Krastitel"-Sofia EAD, Sofia, Bulgaria\|Diagnostic Consultative Center 18 - Sofia EOOD, Sofia, Bulgaria\|MHAT "St. Sofia" EOOD, Sofia, Bulgaria\|Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD, Stara Zagora, Bulgaria\|Multiprofile Hospital for Active Treatment Targovishte AD, Targovishte, Bulgaria\|Outpatient Clinic for Primary Outpatient Medical Care "Puls" - Dr. Mladen Buchvarov EOOD, Tsarevo, Bulgaria\|Medical center Leo Clinic EOOD, Varna, Bulgaria\|Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD, Vratsa, Bulgaria\|Fundacion Centro de Investigacion Clinica CIC, Medellin, Antioquia, Colombia\|Clinica de la Costa LTDA., Barranquilla, Atlantico, Colombia\|Hospital Universidad Del Norte, Soledad, Atlantico, Colombia\|IPS Medicos Internistas de Caldas, Manizales, Caldas, Colombia\|Caimed S.A.S., Yopal, Casanare, Colombia\|Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S, Bogota, Cundinamarca, Colombia\|Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia, Bogotá D.C., Cundinamarca, Colombia\|Bluecare Salud S A S, Bogota, D.c., Colombia\|Fundacion Cardiomet CEQUIN, Armenia, Quindio, Colombia\|Klinika infekcnich nemoci, Hradec Kralove, Czechia\|MEDITRIAL s.r.o., Jindrichuv Hradec III, Czechia\|Zdraví-Fit, s.r.o., Protivín, Czechia\|Nemocnice Slany, Slany, Czechia\|Trial Pharma Kft., Bekescsaba, Hungary\|Semmelweis University Varosmajori Sziv Es Ergyogyaszati Klinika, Budapest, Hungary\|Varosmajori Sziv- es Ergyogyaszati Klinika, Budapest, Hungary\|Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika, Debrecen, Hungary\|Agria-Study Kft., Eger, Hungary\|Trial Pharma Kft., Gyula, Hungary\|Medifarma-98 Kft., Nyiregyhaza, Hungary\|Szent Borbala Korhaz, Tatabanya, Hungary\|Fujita Health University Hospital, Toyoake-City, Aichi, Japan\|Chiba Aoba Municipal Hospital, Chuo-ku, Chiba, Japan\|International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan\|National Hokkaido Medical Center, Sapporo, Hokkaido, Japan\|Rakuwakai Otowa Hospital, Kyoto-shi, Kyoto, Japan\|Rinku General Medical Center, Izumisano, Osaka, Japan\|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan\|Tokyo Shinagawa Hospital, Shinagawa-ku, Tokyo, Japan\|National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan\|Sekino Hospital, Toshimaku, Tokyo, Japan\|Kyushu Medical Center, Fukuoka, Japan\|Chonnam National University Hospital, Gwangju-si, Kwangju-kwangy?kshi, Korea, Republic of\|Pusan National University Hospital, Busan, Korea, Republic of\|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of\|Chonnam National University Bitgoeul Hospital, Gwangju, Korea, Republic of\|Incheon Medical Center, Incheon, Korea, Republic of\|Boramae Medical Center, Seoul, Korea, Republic of\|Seoul Medical Center, Seoul, Korea, Republic of\|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia\|Hospital Taiping, Taiping, Perak, Malaysia\|Hospital Seberang Jaya, Perai, Pulau Pinang, Malaysia\|Hospital Miri, Miri, Sarawak, Malaysia\|Klinik Kesihatan Kuang, Rawang, Selangor, Malaysia\|InfectoLab Consultorios de Especialidad en Infectologia, Tijuana, BAJA California, Mexico\|Clinical Research Institute Saltillo S.A. de C.V., Saltillo, Coahuila, Mexico\|Arke SMO S.A. de C.V, Veracruz, COL. Ignacio Zaragoza, Mexico\|Centro de Investigacion Clinica Del Pacifico SA de CV, Acapulco de Juarez, Guerrero, Mexico\|Asociación Mexicana para la Investigación Clínica A.C., Pachuca de Soto, Hidalgo, Mexico\|Instituto Jalisciense de Metabolismo, S.C., Guadalajara, Jalisco, Mexico\|JM Research, Cuernavaca, Morelos, Mexico\|Christus - Latam Hub Center of Excellence and Innovation Center S.C., Monterrey, Nuevo LEON, Mexico\|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico\|Eukarya Pharmasite S.C., Monterrey, Nuevo LEON, Mexico\|Oaxaca Site Management Organization, Oaxaca de Juarez, Oaxaca, Mexico\|Hospital General de Culiacán "Bernardo J. Gastélum", Culíacan, Sinaloa, Mexico\|Köhler & Milstein Research, Merida, Yucatan, Mexico\|Eme Red Hospitalaria, Mérida, Yucatán, Mexico\|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico\|Instituto de Investigaciones Clínicas para la Salud, Durango, Mexico\|FAICIC Clinical Research, Veracruz, Mexico\|Sociedad de Metabolismo y Corazon S.C., Veracruz, Mexico\|KLIMED Marek Klimkiewicz, Bialystok, Poland\|Krakowskie Centrum Medyczne, Krakow, Poland\|Przychodnia Valeo Medical, Lodz, Poland\|IRMED Ośrodek Badań Klinicznych, Piotrkow Trybunalski, Poland\|Tomasz Blicharski Lubelskie Centrum Diagnostyczne, Swidnik, Poland\|WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland\|Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska, Wroclaw, Poland\|Ponce Medical School Foundation, Inc. CAIMED Center, Ponce, Puerto Rico\|Clinical Research Management Group Inc, Ponce, Puerto Rico\|Advance Medical Research Center, San Juan, Puerto Rico\|MERC Welkom, Welkom, FREE State, South Africa\|Worthwhile Clinical Trials, Benoni, Gauteng, South Africa\|REIMED Vosloorus, Boksburg, Gauteng, South Africa\|Peermed CTC (Pty) Ltd T/A MERC Kempton, Kempton Park, Gauteng, South Africa\|Midrand Medical Centre, Midrand, Gauteng, South Africa\|Global Clinical Trials, Pretoria, Gauteng, South Africa\|The Aurum Institute: Pretoria Clinical Research Centre, Pretoria, Gauteng, South Africa\|Botho ke Bontle Health Services, Pretoria, Gauteng, South Africa\|Emmed Research, Pretoria, Gauteng, South Africa\|Into Research, Pretoria, Gauteng, South Africa\|Clinical Trial Systems (Pty) Ltd, Pretoria, Gauteng, South Africa\|Sandton Medical Clinic, Sandton, Gauteng, South Africa\|FCRN Clinical Trial Centre, Vereeniging, Gauteng, South Africa\|Dr PJ Sebastian Clinical Research Centre, Durban, Kwa-zulu Natal, South Africa\|Synapta Clinical Research Center, Durban, Kwazulu Natal, South Africa\|Ahmed Al-Kadi Private Hospital, Mayville, Durban, Kwazulu-natal, South Africa\|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa\|NHC Thohoyandou CRS, Thohoyandou, Limpopo, South Africa\|MERC Middelburg, Middelburg, Mpumalanga, South Africa\|TASK Eden, George, Western CAPE, South Africa\|Be Part Research Pty (Ltd), Paarl, Western CAPE, South Africa\|Clinical Projects Research, Worcester, Western CAPE, South Africa\|Dr JM Engelbrecht Trial Site, Somerset West, South Africa\|Eba Centelles, Centelles, Barcelona [barcelona], Spain\|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain\|CAP Vicenç Papaceit, La Roca del Valles, Barcelona, Spain\|CAP La Mina, Sant Adria de Besos, Barcelona, Spain\|Hospital Clinico San Carlos, Madrid, Madrid, Comunidad DE, Spain\|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain\|IMED Valencia, Burjassot, Valencia, Spain\|Complexo Hospitalario Universitario da Coruna, A Coruna, Spain\|Complexo Hospitalario Universitario da Coruna, A Coruña, Spain\|Hospital Universitario Virgen de las Nieves, Granada, Spain\|Hospital Universitario de la Paz, Madrid, Spain\|Hospital Universitario de Salamanca, Salamanca, Spain\|Hospital Universitario Virgen de Valme, Sevilla, Spain\|Far Eastern Memorial Hospital, New Taipei City, Taiwan\|China Medical University Hospital, Taichung City, Taiwan\|Taichung Veterans General Hospital, Taichung, Taiwan\|National Taiwan University Hospital, Taipei, Taiwan\|Siriraj Hospital, Mahidol University, BangkokNoi, Bangkok, Thailand\|Riverside Bangkok Hotel, Bangplud, Bangkok, Thailand\|Bangkok Centre Hotel, Bangrak, Bangkok, Thailand\|Chula Filed hospital, Chulalongkorn University Sport center (Chantanayingyong Gymnasium),, Pathum Wan District,, Bangkok, Thailand\|Thai Red Cross Emerging Infectious Diseases (EDI) Clinic, Pathumwan,, Bangkok, Thailand\|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),, Pathumwan, Bangkok, Thailand\|Baiyoke Suite Hotel, Ratchathewi, Bangkok, Thailand\|Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,, Hat Yai, Songkhla, Thailand\|Khon Kaen Univerisity Field Hospital, Student Dormitory 26, Khon Kaen University, Khon Kaen, Thailand\|Srinagarind Hospital, Khon Kaen, Thailand\|Cukurova University Medical Faculty, Balcali, Adana, Turkey\|Ankara University Medical Faculty, Ibni-Sina Hospital, Ankara, Turkey\|Hacettepe University Medical Faculty Hospital, Ankara, Turkey\|Akdeniz Universitesi Hastanesi, Antalya, Turkey\|Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi, Gaziantep, Turkey\|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey\|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey\|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Istanbul, Turkey\|Medipol Mega University Hospital, Istanbul, Turkey\|Acibadem University Atakent Hospital, Istanbul, Turkey\|Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, Turkey\|Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital, Izmir, Turkey\|Kocaeli University Medical Faculty, Kocaeli, Turkey\|Mersin University Medical Faculty, Mersin, Turkey\|Sakarya University Training and Research Hospital, Sakarya, Turkey\|Karadeniz Teknik Universitesi Farabi Hastanesi, Trabzon, Turkey\|Communal Medical Enterprise "Likarnya Prydniprovska", Kremenchuk, Poltava Region, Ukraine\|Regional Communal Nonprofit Institution "Chernivtsi Regional Clinical Hospital", Chernivtsi, Ukraine\|Communal non-commercial Enterprise "City Clinical Hospital №3" of Chernivtsi City Council, Chernivtsi, Ukraine\|Communal non-profit enterprise "City Clinical Hospital #16" of Dnipro City Council, Dnipro, Ukraine\|Municipal Nonprofit Enterprise "Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital of, Ivano-Frankivsk, Ukraine\|Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council", Ivano-Frankivsk, Ukraine\|Municipal Non-profit Enterprise "Ivano-Frankivsk Regional Phthisiopulmonology Center of, Ivano-Frankivsk, Ukraine\|Municipal Nonprofit Enterprise "City Student Hospital" of Kharkiv City Council, Kharkiv, Ukraine\|Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases, Kharkiv, Ukraine\|Municipal Nonprofit Enterprise "City Clinic Hospital # 13" of Kharkiv City Council, Kharkiv, Ukraine\|Municipal Non-profit Enterprise "Oleksandrivska Kyiv City Clinical Hospital" Of Executive Body Of, Kyiv, Ukraine\|Municipal non-commercial enterprise "Kyiv City Clinical Hospital #1" Of Executive Body Of the Kyiv, Kyiv, Ukraine\|Kyiv Railway Clinical Hospital No.2 of Branch "Health Center of the Public Joint Stock Company, Kyiv, Ukraine\|Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company, Kyiv, Ukraine\|Municipal non-profit enterprise of Lviv regional council "Lviv regional phthisiopulmonology clinical, Lviv, Ukraine\|Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4", Lviv, Ukraine\|Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional, Poltava, Ukraine\|Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council, Tarasove Village, Ukraine\|Municipal Non-commercial Enterprise "Vinnytsia City Clinical Hospital №1", Vinnytsia, Ukraine\|Communal Enterprise "Hospital #1" of Zhytomyr City Council, Zhytomyr, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 1150 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Sustained Alleviation of All Targeted COVID-19 Signs/Symptoms\|Percentage of Participants Who Experience Adverse Events (AEs)\|Percentage of Participants Who Experience an AE(s) or Serious Adverse Events (SAEs) that Leads to Study Discontinuation\|Proportion of Participants With Severe Signs/Symptoms Attributed to COVID-19\|Time to Sustained Resolution of All Targeted COVID-19 Signs/Symptoms\|Duration of Each Targeted COVID-19 Sign/Symptom\|Proportion of Participants Progressing to a Worsening Status In 1 or More COVID-19 Signs/Symptoms\|Proportion of Participants With a Resting Peripheral Oxygen Saturation ≥95%\|Number of COVID-19 Related Medical Visits\|Number of Days in Hospital and Intensive Care Unit (ICU) Stay in Participants With COVID-19 Related Hospitalization\|Proportion of Participants With COVID-19 Related Hospitalization or Death From Any Cause\|Proportion of Participants With Death (all cause)\|Minimal Concentration (Ctrough) of PF-07321332\|Viral Titers Measured Via Reverse Transcription Polymerase Chain Reaction (RT-PCR) in Nasal Swabs
NCT04459286	The Nitazoxanide Plus Atazanavir for COVID-19 Study	Terminated	Phase 2	Oct/09/2020	May/02/2021
Alternative id - NACOVID Interventions - Drug: Nitazoxanide and atazanavir/ritonavir\|Other: Standard of Care Study type - Interventional Study results - No Results Available Locations - Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria\|Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 57 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Time to SARS-CoV-2 negativity\|Difference in SARS-CoV-2 AUC\|Time to symptoms resolution\|Clinical status as assessed with the seven-category ordinal scale on days 7 and 14\|Duration of hospitalization in survivors\|Day 28 mortality\|Time from treatment initiation to death\|Proportion with viral RNA detection over time
NCT04365582	OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome	Withdrawn	Phase 3	May/07/2020	Apr/19/2021
Alternative id - OUTCOV Interventions - Drug: Azithromycin\|Drug: Hydroxychloroquine\|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 50 Years and older (Adult, Older Adult) Outcome measures - Hospital admission\|Effect of treatment on Death at D20\|Effect of treatment on Death at D60\|Effect of treatment on Death due to COVID at D20\|Effect of treatment on Death due to COVID at D60\|Effect of treatment on need for ICU stay at D20\|Effect of treatment on need for ICU stay at D60\|Effect of treatment on duration of ICU stay at D20\|Effect of treatment on duration of ICU stay at D60\|Effect of treatment on need of mechanical ventilation at D20\|Effect of treatment on need of mechanical ventilation at D60\|Effect of treatment on duration of mechanical ventilation at D20\|Effect of treatment on duration of mechanical ventilation at D60\|Effect of treatment on time to hospitalization at D20\|Effect of treatment on time to hospitalization at D60\|Effect of treatment on Duration of Hospital stay et D20\|Effect of treatment on Duration of Hospital stay et D60\|Effect of treatment on Duration of symptoms at D20\|Effect of treatment on Duration of symptoms at D60\|Incidence of Treatment-Emergent Adverse Events
NCT04331470	Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19	Recruiting	Phase 2\|Phase 3	Apr/04/2020	May/20/2020
Alternative id - 97548 Interventions - Drug: Levamisole Pill + Budesonide+Formoterol inhaler\|Drug: Lopinavir/Ritonavir + hydoxychloroquine Study type - Interventional Study results - No Results Available Locations - Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 30 Age - 15 Years to 100 Years (Child, Adult, Older Adult) Outcome measures - Clear chest CT-scan\|PCR test\|Physical statues of patient
NCT04295551	Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)	Unknown status	Not Applicable	Mar/14/2020	Apr/14/2021
Alternative id - QF-XYP1990-1 Interventions - Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection\|Drug: Lopinavir/ritonavir treatment Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 80 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Clinical recovery time
NCT04350671	Interferon Beta 1a in Hospitalized COVID-19 Patients	Enrolling by invitation	Phase 4	Apr/15/2020	Apr/24/2020
Alternative id - Interferon Beta 1a in COVID-19 Interventions - Drug: Interferon Beta-1A\|Drug: Lopinavir / Ritonavir\|Drug: Single Dose of Hydroxychloroquine Study type - Interventional Study results - No Results Available Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 40 Age - 50 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization\|Cumulative incidence of serious adverse events
NCT04779047	Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.	Recruiting	Phase 4	Oct/01/2020	Apr/05/2021
Alternative id - REC-H-PhBSU-21011 Interventions - Drug: Remdesivir\|Drug: Hydroxychloroquine\|Drug: Tocilizumab\|Drug: Lopinavir/ Ritonavir\|Drug: Ivermectin Study type - Interventional Study results - No Results Available Locations - Beni-suef University, Banī Suwayf, Egypt Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 150 Age - 18 Years to 88 Years (Adult, Older Adult) Outcome measures - Percentage of clinical cure in each arm
NCT04315948	Trial of Treatments for COVID-19 in Hospitalized Adults	Recruiting	Phase 3	Mar/22/2020	Mar/01/2023
Alternative id - C20-15\|101015736 Interventions - Drug: Remdesivir\|Drug: Lopinavir/ritonavir\|Drug: Interferon Beta-1A\|Drug: Hydroxychloroquine\|Other: Standard of care\|Drug: AZD7442\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Medizinische Universität Innsbruck, Innsbruck, Austria\|Kepler Universitätsklinikum Linz, Linz, Austria\|Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria\|Hôpital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium\|Hôpital Saint Luc, Brussels, Belgium\|CHU Brugmann, Brussels, Belgium\|Hôpital La Citadelle, Liège, Belgium\|Pôle Hospitalier Jolimont / site de Mons-Warquignies, Mons, Belgium\|Fakultní nemocnice u sv. Anny v Brně, Brno, Czechia\|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France\|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France\|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France\|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France\|CHU APHP Ambroise-Paré, Boulogne-Billancourt, France\|Centre Hospitalier Andrée Rosemon, Cayenne, France\|CHU Clermont-Ferrand, Clermont-Ferrand, France\|Hospices Civil, Colmar, France\|APHP - hôpital Henri-Mondor, Créteil, France\|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France\|Centre Hospitalier Universitaire de Martinique, Fort De France, France\|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France\|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France\|Centre hospitalier de Versailles, Le Chesnay, France\|Centre Hospitalier Régional Universitaire de Lille, Lille, France\|Hospices Civils de Lyon, Lyon, France\|Centre Hospitalier de Mont de Marsan, Mont-de-Marsan, France\|Centre Hospitalier Universitaire de Montpellier, Montpellier, France\|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France\|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France\|Centre Hospitalier Universitaire de Nantes, Nantes, France\|Centre Hospitalo-Universitaire de Nice, Nice, France\|CHU Nîmes, Nîmes, France\|APHP - Hôpital Lariboisière, Paris, France\|APHP - Hôpital Saint Louis, Paris, France\|APHP - Hôpital Saint Antoine, Paris, France\|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France\|APHP - Hôpital Cochin, Paris, France\|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France\|APHP - Hôpital Necker, Paris, France\|APHP- Hôpital Européen Georges-Pompidou, Paris, France\|APHP - Hôpital Bichat Claude Bernard, Paris, France\|APHP - Hôpital Tenon, Paris, France\|CHU Poitiers, Poitiers, France\|CH Cornouaille, Quimper, France\|CHU de Reims, Reims, France\|Centre Hospitalier Universitaire de Rennes, Rennes, France\|Hopital DELAFONTAINE, Saint-Denis, France\|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France\|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France\|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France\|Centre Hospitalier Universitaire de Toulouse, Toulouse, France\|Centre Hospitalier Universitaire de Toulouse, Toulouse, France\|Centre Hospitalier de Tourcoing, Tourcoing, France\|Centre Hospitalier Universitaire de Tours, Tours, France\|CH Bretagne Atlantique, Vannes, France\|CH Bretagne Atlantique, Vannes, France\|Centre Hospitalier Annecy Genevois, Épagny, France\|Evaggelismos General Hospital, Athens, Greece\|General University Hospital of Patras, Patras, Greece\|hospital Saint James, Dublin, Ireland\|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg\|Hôpitaux Robert Schuman, Luxembourg, Luxembourg\|Akershus Unniversity Hospital, Oslo, Norway\|Lovisenberg Diaconal Hospital, Oslo, Norway\|Oslo University Hospital, Oslo, Norway\|Bienganski Hospital, Łódź, Poland\|Hospital de Abrantes (CHMT), Abrantes, Portugal\|Hospital de Cascais, Cascais, Portugal\|CHULN- Hospital de Santa Maria, Lisboa, Portugal\|CHULN- Hospital de Santa Maria, Lisboa, Portugal\|Centro Hospitalar Universitário de São João, EPE, Porto, Portugal\|Martin University Hospital, Martin, Slovakia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 2416 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Percentage of subjects reporting each severity rating on a 7-point ordinal scale\|Status on an ordinal scale\|National Early Warning Score 2 (NEWS-2 score)\|Number of oxygenation free days in the first 28 days\|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.\|Ventilator free days in the first 28 days\|Incidence of new mechanical ventilation use during the trial.\|Need for mechanical ventilation or death by Day 15\|Hospitalization\|Mortality\|Occurrence of new hospitalization\|Occurrence of confirmed re-infection with SARS-CoV-2\|Cumulative incidence of serious adverse events (SAEs)\|Cumulative incidence of Grade 1- 2 hypersensitivity- related and infusion related AEs until D29 visit\|Cumulative incidence of Grade 3 and 4 adverse events (AEs)\|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)\|Cumulative incidence of AEs of Special Interest
NCT04409483	Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger	Withdrawn	Phase 3	Jun/01/2020	Dec/31/2020
Alternative id - Trascov Interventions - Drug: Lopinavir-Ritonavir Drug Combination\|Combination Product: Standard Care Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 12 Years and older (Child, Adult, Older Adult) Outcome measures - Hospitalization or death\|All-cause mortality\|Time to hospitalization\|Length of hospitalization\|Admission to intensive care\|Adverse events\|Serious adverse events
NCT04328285	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	Active, not recruiting	Phase 3	Apr/14/2020	Mar/30/2022
Alternative id - 20PH061\|2020-001188-96 Interventions - Drug: Hydroxychloroquine\|Drug: Placebo of Hydroxychloroquine\|Drug: Lopinavir and ritonavir\|Drug: Placebo of LPV/r Tablets Study type - Interventional Study results - No Results Available Locations - CHU d'Angers, Angers, France\|CHU de Bordeaux, Bordeaux, France\|CHU de Clermont-Ferrand, Clermont-ferrand, France\|CHU de Montpellier, Montpellier, France\|CHU de Nancy, Nancy, France\|CHU de Nantes, Nantes, France\|CHU de Rennes, Rennes, France\|CHU de Rouen, Rouen, France\|CHU de Saint-Etienne, Saint-Étienne, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 1200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)\|Evaluation of the occurrence of adverse events in each arm,\|Evaluation of the discontinuation rates of the investigational drug in each arm,\|Evaluation of the adherence of participants to study drug,\|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,\|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm\|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.\|corrected QT interval (ms)
NCT04425382	Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar	Recruiting		Mar/01/2020	Sep/01/2020
Alternative id - MRC-05-069 Interventions - Drug: Darunavir/Cobicistat\|Drug: Lopinavir/Ritonavir Study type - Observational Study results - No Results Available Locations - Hamad Medical Corporation, Doha, Qatar Study designs - Observational Model: Other\|Time Perspective: Retrospective Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)\|Percentage of Virological Clearance\|Percentage of Clinical Deterioration\|Incidence of Adverse Events\|Length of Hospital Stay\|All-cause Mortality
NCT04276688	Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment	Completed	Phase 2	Feb/10/2020	Mar/31/2020
Alternative id - UW-20-074 Interventions - Drug: Lopinavir/ritonavir\|Drug: Ribavirin\|Drug: Interferon Beta-1B Study type - Interventional Study results - No Results Available Locations - University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 127 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to negative NPS\|Time to negative saliva\|Time to clinical improvement\|Hospitalisation\|Mortality\|Immune reaction\|Adverse events\|Time to negative all clinical specimens
NCT04380818	Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19	Recruiting	Not Applicable	Jun/05/2020	Nov/01/2021
Alternative id - IPACOVID Interventions - Radiation: Low-dose radiotherapy\|Drug: Hydroxychloroquine Sulfate\|Drug: Ritonavir/lopinavir\|Drug: Tocilizumab Injection [Actemra]\|Drug: Azithromycin\|Drug: Corticosteroid\|Drug: Low molecular weight heparin\|Device: Oxygen supply Study type - Interventional Study results - No Results Available Locations - Hospital Sant Joan de Reus, Reus, Tarragona, Spain\|Hospital Del Mar, Barcelona, Spain\|Hospital Universitario Madrid Sanchinarro, Madrid, Spain Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 106 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%\|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\|Change of the radiological image\|Overall mortality\|Measure of pro-inflammatory interleukins\|Measure of trasforming growth factor (TGF-b)\|Measure of tumor necrosis factor alpha (TNF-a)\|Determining overexpression of pro-inflammatory selectin\|Determining cell adhesion molecules (CAMs)\|Measure of marker of oxidative stress PON-1
NCT04275388	Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia	Not yet recruiting		May/15/2020	Dec/14/2021
Alternative id - QF-XYP2001-1 Interventions - Drug: Xiyanping injection\|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 426 Age - up to 100 Years (Child, Adult, Older Adult) Outcome measures - Clinical recovery time\|Complete fever time\|Cough relief time\|Virus negative time\|Incidence of severe or critical neocoronavirus pneumonia
NCT04345276	Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection	Completed	Phase 4	Mar/18/2020	Apr/15/2020
Alternative id - ASC-CTP-HS-01 Interventions - Drug: Danoprevir+Ritonavir Study type - Interventional Study results - No Results Available Locations - Huoshenshan Hostipal, Wuhan, Hubei, China Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Rate of composite adverse outcomes\|Time to recovery\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no requiring supplemental oxygen\|Rate of undetectable New coronavirus pathogen nucleic acid\|Rate of mechanical ventilation\|Rate of ICU admission\|Rate of serious adverse event
NCT05261139	EPIC-Peds: Study of Oral PF-07321332 (Nirmatrelvir)/Ritonavir in Nonhospitalized COVID-19 Pediatric Patients at Risk for Severe Disease	Not yet recruiting	Phase 3	Mar/02/2022	Mar/04/2023
Alternative id - C4671026 Interventions - Drug: nirmatrelvir\|Drug: ritonavir Study type - Interventional Study results - No Results Available Locations - SKY Clinical Research Network Group-Quinn, Ridgeland, Mississippi, United States\|Coastal Pediatric Research, Summerville, South Carolina, United States\|Consano Clinical Research, LLC, Shavano Park, Texas, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 140 Age - up to 18 Years (Child, Adult) Outcome measures - Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir\|Cohort 3-5: Cmax of nirmatrelvir and ritonavir\|Cohort 1-2: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir\|Cohort 3-5: AUC0-tau of nirmatrelvir and ritonavir\|Incidence of TEAEs, SAEs, AEs leading to discontinuations, and vital sign measurements\|Viral load assessment titers measured via reverse transcription polymerase chain reaction (RT-PCR) in nasal swabs over time\|Proportion of participants with COVID-19 related hospitalization or death from any cause\|Patient assessment on palatability of nirmatrelvir (film-coated tablets and age-appropriate formulation)\|Patient assessment on palatability of ritonavir (age-appropriate formulation)\|Patient assessment on acceptability of nirmatrelvir (film-coated tablets and age-appropriate formulation)\|Patient assessment on acceptability of ritonavir (age-appropriate formulation)
NCT04381936	Randomised Evaluation of COVID-19 Therapy	Recruiting	Phase 2\|Phase 3	Mar/19/2020	Nov/01/2032
Alternative id - NDPHRECOVERY\|2020-001113-21\|ISRCTN50189673 Interventions - Drug: Lopinavir-Ritonavir\|Drug: Corticosteroid\|Drug: Hydroxychloroquine\|Drug: Azithromycin\|Biological: Convalescent plasma\|Drug: Tocilizumab\|Biological: Immunoglobulin\|Drug: Synthetic neutralising antibodies\|Drug: Aspirin\|Drug: Colchicine\|Drug: Baricitinib\|Drug: Anakinra\|Drug: Dimethyl fumarate\|Drug: High Dose Corticosteroid\|Drug: Empagliflozin\|Drug: Sotrovimab Study type - Interventional Study results - No Results Available Locations - Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana\|Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India\|Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia\|Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal\|Wits Health Consortium, Johannesburg, South Africa\|RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U, Colombo, Sri Lanka\|Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom\|Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 50000 Age - Child, Adult, Older Adult Outcome measures - All-cause mortality\|Duration of hospital stay\|Composite endpoint of death or need for mechanical ventilation or ECMO
NCT05032950	Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants	Completed	Phase 1	Sep/17/2021	Dec/09/2021
Alternative id - C4671013\|2021-003590-62 Interventions - Drug: Midazolam\|Drug: PF-07321332/ritonavir + Midazolam\|Drug: Ritonavir + Midazolam Study type - Interventional Study results - No Results Available Locations - Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 12 Age - 18 Years to 60 Years (Adult) Outcome measures - Maximum Observed Plasma Concentration (Cmax) of midazolam when administered alone\|Cmax of midazolam when administered with PF-07321332/ritonavir\|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of midazolam when administered alone\|AUCinf of midazolam when administered with PF-07321332/ritonavir\|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of midazolam when administered alone\|AUClast of midazolam when administered with PF-07321332/ritonavir\|Assessment of Participants With Treatment-Emergent Adverse Events (TEAEs) of PF-07321332/Ritonavir\|Assessment of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities of PF-07321332/Ritonavir\|Assessment of Participants With Clinically Significant Change From Baseline in Vital Signs of PF-07321332/Ritonavir\|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings of PF-07321332/Ritonavir\|Cmax of midazolam when administered with ritonavir\|AUCinf of midazolam when administered with ritonavir\|AUClast of midazolam when administered with ritonavir\|Apparent Oral Clearance (CL/F) of midazolam when administered alone\|CL/F of midazolam when administered with PF-07321332/ritonavir\|Apparent Oral Volume of Distribution (Vz/F)) of midazolam when administered alone\|Vz/F of midazolam when administered with PF-07321332/ritonavir\|Time to Cmax (Tmax) of midazolam when administered alone\|Tmax of midazolam when administered with PF-07321332/ritonavir\|Plasma Decay Half-Life (t1/2) of midazolam when administered alone\|t1/2 of midazolam when administered with PF-07321332/ritonavir
NCT04909853	Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.	Completed	Phase 1	Jun/15/2021	Oct/07/2021
Alternative id - C4671011 Interventions - Drug: PF-07321332/ritonavir Study type - Interventional Study results - No Results Available Locations - Orange County Research Center, Tustin, California, United States\|Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Miami, Florida, United States\|University of Miami Division of Clinical Pharmacology, Miami, Florida, United States\|Genesis Clinical Research, Tampa, Florida, United States\|Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 35 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Maximum observed plasma concentration (Cmax) for PF-07321332.\|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07321332\|Amount of PF-07321332 excreted in urine unchanged\|Time to maximum concentration (Tmax) of PF-07321332\|Area Under the Plasma Concentration-time Profile from Time 0 to Last Measurable PF-07321332 Concentration (AUClast)\|Number of Participants reporting Treatment-Emergent Adverse Events\|Number of Participants With Clinical Laboratory Abnormalities\|Number of Participants With Vital Signs Abnormalities\|Number of Participants With Abnormalities in Physical Examination\|Number of Participants With Abnormal Electrocardiogram (ECG)
NCT04386876	Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions	Completed	Phase 1	Apr/30/2020	Jun/11/2020
Alternative id - NOV2020/01911\|FARGE365 Interventions - Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet\|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet Study type - Interventional Study results - No Results Available Locations - Novagenix Drug R&D Center, Akyurt, Ankara, Turkey\|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 30 Age - 20 Years to 40 Years (Adult) Outcome measures - Primary PK End Points
NCT04261907	Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection	Unknown status	Not Applicable	Feb/07/2020	Jun/30/2020
Alternative id - ASC09F-CTP-ZY-01 Interventions - Drug: ASC09/ritonavir group\|Drug: lopinavir/ritonavir group Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 160 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - The incidence of composite adverse outcome\|Time to recovery\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no requring supplemental oxygen\|Rate of undectable viral RNA\|Rate of mechanical ventilation\|Rate of ICU admission\|Time and rate of laboratory indicators related to disease improvement to return to normal
NCT04455958	Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year	Withdrawn	Phase 2	May/01/2021	Nov/01/2021
Alternative id - STUDY00021444\|NCI-2020-02877 Interventions - Drug: Lopinavir/Ritonavir\|Drug: Placebo Administration\|Other: Questionnaire Administration Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Severity of symptoms\|Clinical benefit rate of lopinavir/ritonavir\|Time to symptom progression\|Time to improvement of participants\|Time to hospital admission for those who develop severe of critical symptoms\|Intensive care unit (ICU) admission: yes or no\|Receiving ventilator support: yes or no\|Overall survival
NCT04354428	Treatment for COVID-19 in High-Risk Adult Outpatients	Active, not recruiting	Phase 2\|Phase 3	Apr/16/2020	Jan/01/2021
Alternative id - STUDY00009878\|INV-017062 Interventions - Drug: Ascorbic Acid\|Drug: Hydroxychloroquine Sulfate\|Drug: Azithromycin\|Drug: Folic Acid\|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] Study type - Interventional Study results - No Results Available Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States\|Tulane University, New Orleans, Louisiana, United States\|Boston University, Boston, Massachusetts, United States\|SUNY Upstate Medical University, Syracuse, New York, United States\|University of Washington Coordinating Center, Seattle, Washington, United States\|UW Virology Research Clinic, Seattle, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 300 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Lower respiratory tract infection (LRTI) rates\|Incidence of hospitalization or mortality\|Change in upper respiratory viral shedding\|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]\|Rate of participant-reported adverse events\|COVID-19-related hospitalization days\|Rate of disease severity\|Viral shedding rates\|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
NCT04960202	EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19	Active, not recruiting	Phase 3	Jul/16/2021	Apr/23/2022
Alternative id - C4671005\|2021-002895-38\|EPIC-HR Interventions - Drug: PF-07321332\|Drug: Ritonavir\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Cahaba Research, Inc., Pelham, Alabama, United States\|The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States\|The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States\|Hope Clinical Research, Canoga Park, California, United States\|Ascada Research, Fullerton, California, United States\|Atella Clinical Research LLC., La Palma, California, United States\|Ark Clinical Research, Long Beach, California, United States\|American Institute of Research, Los Angeles, California, United States\|South Bay Clinical Research Institute, Torrance, California, United States\|Hope Clinical Research (COVID Satellite Site), West Hills, California, United States\|Future Innovative Treatments, LLC, Colorado Springs, Colorado, United States\|Xera Med Research, Boca Raton, Florida, United States\|MOORE Clinical Research, Inc., Brandon, Florida, United States\|Innovative Research of West Florida, Inc., Clearwater, Florida, United States\|Herco Medical and Research Center Inc, Coral Gables, Florida, United States\|Advance Clinical Research Group, Cutler Bay, Florida, United States\|Beautiful Minds Clinical Research Center, Cutler Bay, Florida, United States\|Unlimited Medical Research Group, LLC, Hialeah Gardens, Florida, United States\|Qway Research, LLC, Hialeah, Florida, United States\|Eastern Research Inc, Hialeah, Florida, United States\|Inpatient Research Clinic, Hialeah, Florida, United States\|Doral Medical Research LLC., Hialeah, Florida, United States\|Doral Medical Research,LLC, Hialeah, Florida, United States\|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States\|Savin Medical Group, LLC, Miami Lakes, Florida, United States\|Angels Clinical Research Institute, Miami, Florida, United States\|LCC Medical Research Institute, LLC, Miami, Florida, United States\|Premium Medical Research Corp, Miami, Florida, United States\|Global Health Clinical Trials Corp, Miami, Florida, United States\|South Florida Research Center, Inc., Miami, Florida, United States\|Suncoast Research Group, LLC, Miami, Florida, United States\|I.V.A.M. Clinical & Investigational Center, LLC, Miami, Florida, United States\|C'A Research, Miami, Florida, United States\|ProLive Medical Research, Corp., Miami, Florida, United States\|Entrust Clinical Research, Miami, Florida, United States\|Reed Medical Research, Miami, Florida, United States\|Kendall South Medical Center, Miami, Florida, United States\|Clinical Site Partners, Inc d/b/a CSP Miami, Miami, Florida, United States\|Coral Research Clinic Corp, Miami, Florida, United States\|Omega Research Orlando, LLC, Orlando, Florida, United States\|NAPA Research LLC, Pompano Beach, Florida, United States\|CDC Research Institute, Port Saint Lucie, Florida, United States\|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States\|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States\|USPA Advance Concept Medical Research Group LLC, South Miami, Florida, United States\|Sunrise Research Institute, Sunrise, Florida, United States\|Santos Research Center, CORP, Tampa, Florida, United States\|Clinical Site Partners, Inc. dba CSP Orlando, Winter Park, Florida, United States\|Research by Design, LLC, Chicago, Illinois, United States\|New Orleans Sinus Center (COVID-19 Testing), Marrero, Louisiana, United States\|Tandem Clinical Research GI, LLC, Marrero, Louisiana, United States\|Mercury Street Medical Group, PLLC, Butte, Montana, United States\|Excel Clinical Research, Las Vegas, Nevada, United States\|Meridian Clinical Research, LLC, Endwell, New York, United States\|Monroe Biomedical Research, Monroe, North Carolina, United States\|Accellacare, Wilmington, North Carolina, United States\|Premier Medical Group, Clarksville, Tennessee, United States\|PharmaTex Research, LLC, Amarillo, Texas, United States\|ARC Clinical Research at William Cannon, Austin, Texas, United States\|St Hope Foundation, Bellaire, Texas, United States\|Conroe Willis Medical Research, Conroe, Texas, United States\|South Texas Clinical Research, Corpus Christi, Texas, United States\|SignatureCare Emergency Center, Houston, Texas, United States\|Trio Clinical Trials, LLC, Houston, Texas, United States\|C & R Research Services USA, Houston, Texas, United States\|Next Level Urgent Care, Houston, Texas, United States\|SMS Clinical Research, LLC, Mesquite, Texas, United States\|SMS Clinical Research, Mesquite, Texas, United States\|LinQ Research, LLC, Pearland, Texas, United States\|Epic Medical Research, Red Oak, Texas, United States\|Sun Research Institute, San Antonio, Texas, United States\|BFHC Research, San Antonio, Texas, United States\|Tranquility Research, Webster, Texas, United States\|TPMG (Tidewater Physicians Multispecialty Group) Clinical Research, Newport News, Virginia, United States\|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina\|Hospital De Clínicas Presidente Dr.Nicolas Avellaneda, San Miguel de Tucuman, Tucuman, Argentina\|Chronos Pesquisa Clinica, Brasilia, Distrito Federal, Brazil\|Hospital Agamenon Magalhaes, Recife, Pernambuco, Brazil\|Centro de Estudos Clinicos do Interior Paulista (CECIP), Jau, SAO Paulo, Brazil\|Individual Practice for Primary Medical Care - IPPMC - Dr. P. Panayotov EOOD, Burgas, Bulgaria\|"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd, Haskovo, Bulgaria\|MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD, Kozloduy, Bulgaria\|Diagnostic-Consultative Center I Lom EOOD, Lom, Bulgaria\|Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD, Lom, Bulgaria\|Medical centre Leo Clinic EOOD, Lovech, Bulgaria\|MHAT Heart and Brain EAD, Pleven, Bulgaria\|DCC Sveti Georgi EOOD, Plovdiv, Bulgaria\|MHAT "St. Panteleimon "- Plovdiv, Plovdiv, Bulgaria\|Multiprofile Hospital for Active Treatment Sveti Ivan Rilski - Razgrad AD, Razgrad, Bulgaria\|"Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -, Ruse, Bulgaria\|UMHAT Medica Ruse OOD, Ruse, Bulgaria\|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria\|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria\|Multiprofile Hospital For Active Treatment Shumen AD, Shumen, Bulgaria\|Multiprofile hospital for active treatment - Sliven to Military Medical Academy, Sliven, Bulgaria\|MHAT "Dr. Ivan Seliminski" AD, Sliven, Sliven, Bulgaria\|Diagnostic-Consultative Center XXII- Sofia ЕООD, Sofia, Bulgaria\|MHAT "St. Sofia" EOOD, Sofia, Bulgaria\|Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD, Stara Zagora, Bulgaria\|Multiprofile Hospital for Active Treatment Targovishte AD, Targovishte, Bulgaria\|Outpatient Clinic for Primary Outpatient Medical Care "Puls" - Dr. Mladen Buchvarov EOOD, Tsarevo, Bulgaria\|Medical center Leo Clinic EOOD, Varna, Bulgaria\|Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD, Vratsa, Bulgaria\|Fundacion Cardiomet CEQUIN, Armenia, Quindio, Colombia\|Zdraví-Fit, s.r.o., Protivín, Czechia\|Nemocnice Slany, Slany, Czechia\|Trial Pharma Kft., Bekescsaba, Hungary\|Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika, Debrecen, Hungary\|Agria-Study Kft., Eger, Hungary\|Trial Pharma Kft., Gyula, Hungary\|Medifarma-98 Kft., Nyiregyhaza, Hungary\|AIIMS Raipur, Raipur, Chhattisgarh, India\|Jupiter Hospital, Vadodara, Gujarat, India\|BGS Global Institute of Medical Sciences and Hospital, Bangalore, Karnataka, India\|Lisie Hospital, Kochi, Kerala, India\|Jehangir Clinical Development Centre Pvt. Ltd, Pune, Maharashtra, India\|Lifepoint Research LLP, Pune, Maharashtra, India\|Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India\|Apex Hospitals Pvt Ltd, Jaipur, Rajasthan, India\|Maharaja Agrasen Superspeciality Hospital, Jaipur, Rajasthan, India\|Nil Ratan Sircar Medical College and Hospital, Kolkata, WEST Bengal, India\|Aakash Healthcare Private Limited, New Delhi, India\|Sardar Patel Medical College, Pavan PURI Bikaner, Rajasthan, India\|International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan\|National Hokkaido Medical Center, Sapporo, Hokkaido, Japan\|Rinku General Medical Center, Izumisano, Osaka, Japan\|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan\|National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan\|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of\|Incheon Medical Center, Incheon, Korea, Republic of\|Chonnam National University Bitgoeul Hospital, Nam-gu, Korea, Republic of\|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of\|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia\|Hospital Miri, Miri, Sarawak, Malaysia\|Clinical Research Institute Saltillo S.A. de C.V., Saltillo, Coahuila, Mexico\|Asociacion Mexicana para la Investigacion Clinica A.C. (AMIC), Pachuca de Soto, Hidalgo, Mexico\|Instituto Jalisciense de Metabolismo, CS, Guadalajara, Jalisco, Mexico\|JM Research, Cuernavaca, Morelos, Mexico\|Christus - Latam Hub Center of Excellence and Innovation Center S.C., Monterrey, Nuevo LEON, Mexico\|Eukarya Pharmasite S.C., Monterrey, Nuevo LEON, Mexico\|Oaxaca Site Management Organization, Oaxaca de Juarez, Oaxaca, Mexico\|InfectoLab Consultorios de Especialidad en Infectologia, Baja California, Tijuana, Mexico\|Kohler & Milstein Research S.A. de C.V., Merida, Yucatan, Mexico\|Eme Red Hospitalaria, Mérida, Yucatán, Mexico\|Centro de Investigacion Clinica Del Pacifico SA de CV, Acapulco, Mexico\|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico\|Instituto de Investigaciones Clínicas para la Salud, Durango, Mexico\|FAICIC S. de R.L. de C.V., Veracruz, Mexico\|Sociedad de Metabolismo y Corazon S.C., Veracruz, Mexico\|Arke SMO S.A. de C.V, Veracruz, Mexico\|KLIMED Marek Klimkiewicz, Bialystok, Poland\|Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska, Wroclaw, Poland\|Clinical Research Management Group Inc, Ponce, Puerto Rico\|Advance Medical Research Center, San Juan, Puerto Rico\|LLC Trekhgorka Medicine, Odintsovo, Moscow Region, Russian Federation\|Barnaul City Hospital Number 5, Barnaul, Russian Federation\|KDC "Evromedservis", OJSC, Moscow, Russian Federation\|Smolensk State Medical University, Smolensk, Russian Federation\|MERC Welkom, Welkom, FREE State, South Africa\|East Rand Research Centre T/A Worthwhile Clinical Trials, Benoni, Gauteng, South Africa\|Botho ke Bontle Health Services, Pretoria, Gauteng, South Africa\|Synapta Clinical Research Center, Durban, Kwazulu Natal, South Africa\|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa\|MERC Middelburg, Middelburg, Mpumalanga, South Africa\|Eba Centelles, Centelles, Barcelona [barcelona], Spain\|Complexo Hospitalario Universitario da Coruna, A Coruña, Spain\|Bangkok Centre Hotel, Bangrak, Bangkok, Thailand\|Chula Filed hospital, Chulalongkorn University Sport center (Chantanayingyong Gymnasium),, Pathum Wan District,, Bangkok, Thailand\|Thai Red Cross Emerging Infectious Diseases (EDI) Clinic, Pathumwan,, Bangkok, Thailand\|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),, Pathumwan, Bangkok, Thailand\|Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,, Hat Yai, Songkhla, Thailand\|Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand\|Ankara University Medical Faculty, Ibni-Sina Hospital, Ankara, Turkey\|Hacettepe University Medical Faculty Hospital, Ankara, Turkey\|Akdeniz Universitesi Hastanesi, Antalya, Turkey\|Istanbul Medipol University Clinical Research Ethics Committee, Beykoz / Istanbul, Turkey\|Gaziantep University Medical Faculty, Gaziantep, Turkey\|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey\|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Istanbul, Turkey\|Acibadem Saglik Hizmetleri ve Tic.A.S, Acibadem Atakent Hastanesi, Istanbul, Turkey\|Istanbul Universitesi Klinik Arastirmalar Mukemmeliyet Uygulama ve Arastirma Merkezi, Istanbul, Turkey\|Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, Turkey\|Kocaeli University Medical Faculty, Kocaeli, Turkey\|Sbü Dr. Suat Seren Göğüs Hastaliklari Ve Cerrahisi Eğitim Ve Araştirma Hastanesi, Konak/Izmir, Turkey\|Mersin University Health Research and Application Hospital, Mersin, Turkey\|Sakarya University Training and Research Hospital, Sakarya, Turkey\|Karadeniz Teknik Universitesi Farabi Hastanesi, Trabzon, Turkey\|Communal non-profit enterprise "City Clinical Hospital #16" of Dnipro City Council, Dnipro, Ukraine\|Municipal Nonprofit Enterprise "Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital of, Ivano-Frankivsk, Ukraine\|Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council", Ivano-Frankivsk, Ukraine\|Municipal Nonprofit Enterprise "City Student Hospital" of Kharkiv City Council, Kharkiv, Ukraine\|Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases, Kharkiv, Ukraine\|"Municipal Non-Profit Enterprise "Alexander Clinical Hospital of Kyiv" of the Kyiv City Council, Kyiv, Ukraine\|Municipal non-commercial enterprise "Kyiv City Clinical Hospital #1" Of Executive Body Of the Kyiv, Kyiv, Ukraine\|Kyiv Railway Clinical Hospital No.2 of Branch "Health Center of the Public Joint Stock Company, Kyiv, Ukraine\|Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company, Kyiv, Ukraine\|Municipal NonProfit Enterprise of the Lviv Regional Council Lviv Regional Information and Analitical, Lviv, Ukraine\|Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4", Lviv, Ukraine\|Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional, Poltava, Ukraine\|Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council, Tarasove Village, Ukraine\|Municipal Non-commercial Enterprise "Vinnytsia City Clinical Hospital №1", Vinnytsia, Ukraine\|Communal Enterprise "Hospital #1" of Zhytomyr City Council, Zhytomyr, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 2246 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of participants with COVID-19 related hospitalization or death from any cause\|Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)of PF-07321332/ritonavir relative to placebo\|Incidence of Treatment-emergent Adverse Events (TEAEs) of PF-07321332/ritonavir relative to placebo of PF-07321332/ritonavir relative to placebo\|Duration of each targeted COVID-19 sign/symptom\|Severity of each targeted COVID-19 sign/symptom\|Proportion of participants with death (all cause)\|To determine the pharmacokinetics (PK) in plasma and whole blood of PF-07321332 in nonhospitalized symptomatic adult participants with COVID 19 who are at increased risk of progression to severe disease\|Viral titers measured by Reverse Transcription Polymerase Chain Reaction (RT-PCR) in nasal swabs\|Number of COVID-19 related medical visits other than hospitalization\|Number of days in hospital and intensive care unit for the treatment of COVID-19
NCT04343768	An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	Completed	Phase 2	Apr/09/2020	Apr/27/2020
Alternative id - Different Interferons in COVID Interventions - Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir\|Drug: Interferon Beta-1A\|Drug: Interferon Beta-1B Study type - Interventional Study results - No Results Available Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization
NCT04372628	Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19	Active, not recruiting	Phase 2	Jun/01/2020	Jun/01/2022
Alternative id - 200827 Interventions - Drug: Lopinavir/Ritonavir 400 mg/100 mg\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - University of Colorado School of Medicine, Aurora, Colorado, United States\|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States\|University of Mississippi Medical Center, Jackson, Mississippi, United States\|Vanderbilt University Medical Center, Nashville, Tennessee, United States\|Intermountain, Murray, Utah, United States\|University of Wisconsin, Madison, Wisconsin, United States Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 600 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Modified COVID Ordinal Outcomes Scale: Study Day 15\|Modified COVID Ordinal Outcome Scale: Study Day 8\|Modified COVID Ordinal Outcome Scale: Study Day 29\|Proportion of patients hospitalized: Day 1 to 29\|Time to hospitalization Day 1 to Day 29\|Time to symptom resolution: Day 1 to Day 29\|All-cause, all-location mortality: Day 1 to Day 29\|Oxygen-free days: Day 1 to Day 29\|Fever-free days: Day 1 to Day 29\|Ventilator-free days: Day 1 to Day 29\|ICU-free days: Day 1 to Day 29\|Hospital-free days: Day 1 to Day 29
NCT04364022	Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland	Completed	Phase 3	Apr/23/2020	Mar/24/2021
Alternative id - CCER 2020-00864 Interventions - Drug: Lopinavir/ritonavir Study type - Interventional Study results - No Results Available Locations - Instituto Nacional de Infectiologia Evandro Chagas, Fiocruz, Rio De Janeiro, Brazil\|Universitätsspital Basel and SwissTPH, Basel, Switzerland\|Hôpitaux Universitaires de Genève, Geneva, Switzerland\|Ospedale Regionale di Lugano, Lugano, Switzerland Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 326 Age - 16 Years and older (Child, Adult, Older Adult) Outcome measures - 21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).\|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)\|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)\|Severity of clinical COVID-19 on a 7-point ordinal scale
NCT04252885	The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection	Completed	Phase 4	Jan/28/2020	May/31/2020
Alternative id - GZ8H-V1.0 20200122 Interventions - Drug: Lopinavir and Ritonavir Tablets\|Drug: Arbidol Study type - Interventional Study results - No Results Available Locations - Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 86 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - The rate of virus inhibition\|The disease prorogation-temperature\|The disease prorogation-respiratory function 1\|The disease prorogation-respiratory function 2\|The disease prorogation-respiratory function 3
NCT04286503	The Clinical Study of Carrimycin on Treatment Patients With COVID-19	Unknown status	Phase 4	Feb/23/2020	Feb/28/2021
Alternative id - BeijingYouan Hospital Interventions - Drug: Carrimycin\|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate\|Drug: basic treatment Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 520 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Fever to normal time (day)\|Pulmonary inflammation resolution time (HRCT) (day)\|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment
NCT05005312	Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332	Completed	Phase 1	Aug/31/2021	Dec/07/2021
Alternative id - C4671010 Interventions - Drug: PF-07321332\|Drug: Ritonavir Study type - Interventional Study results - No Results Available Locations - Orange County Research Center, Tustin, California, United States\|Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 17 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Maximum observed plasma concentration (Cmax) for PF-07321332\|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Last Measurable Time (AUClast) for PF-07321332\|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07321332\|Incidence of Treatment Emergent Adverse Events\|Incidence of Abnormal ECGs\|Incidence of Abnormal Vital Signs\|Incidence of Abnormal Laboratory Values
NCT05263908	General Investigation for PAXLOVID PACK	Not yet recruiting		Mar/01/2022	Jul/10/2023
Alternative id - C4671018 Interventions - Drug: nirmatrelvir / ritonavir Study type - Observational Study results - No Results Available Locations - Pfizer Local County, Tokyo, Japan Study designs - Observational Model: Case-Only\|Time Perspective: Prospective Enrollment - 3300 Age - 12 Years and older (Child, Adult, Older Adult) Outcome measures - Incidence of adverse drug reactions\|Ratio of subjects with worsening severity
NCT04255017	A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia	Unknown status	Phase 4	Feb/01/2020	Jul/01/2020
Alternative id - TJ20200128 Interventions - Drug: Abidol hydrochloride\|Drug: Oseltamivir\|Drug: Lopinavir/ritonavir Study type - Interventional Study results - No Results Available Locations - Department and Institute of Infectious Disease, Wuhan, Hubei, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 400 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Rate of disease remission\|Time for lung recovery\|Rate of no fever\|Rate of respiratory symptom remission\|Rate of lung imaging recovery\|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery\|Rate of undetectable viral RNA
NCT04261270	A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia	Unknown status	Phase 3	Feb/01/2020	Jul/01/2020
Alternative id - ASC09F-CTP-TJ-01 Interventions - Drug: ASC09F+Oseltamivir\|Drug: Ritonavir+Oseltamivir\|Drug: Oseltamivir Study type - Interventional Study results - No Results Available Locations - Department and Institute of Infectious Disease, Wuhan, Hubei, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years to 55 Years (Adult) Outcome measures - Rate of comprehensive adverse outcome\|Time of clinical remission\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no need for oxygen inhalation\|Rate of undetectable viral RNA\|Rate of mechanical ventilation\|Rate of ICU admission\|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery
NCT04499677	FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals	Completed	Phase 2	Sep/24/2020	Dec/01/2021
Alternative id - 132084 Interventions - Drug: Favipiravir\|Drug: Lopinavir/ Ritonavir\|Other: Favipiravir Placebo\|Other: Lopinavir/ Ritonavir Placebo Study type - Interventional Study results - No Results Available Locations - Royal Free Hospital, London, United Kingdom\|University College London Hospital (UCLH), London, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 240 Age - 18 Years to 70 Years (Adult, Older Adult) Outcome measures - Upper respiratory tract viral load at Day 5\|Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy\|Proportion of participants with undetectable stool viral load after 7 days of therapy.\|Rate of decrease in upper respiratory tract viral load during 7 days of therapy\|Duration of fever following commencement of medication\|Proportion of participants with hepatotoxicity after 7 days of therapy\|Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation\|Proportion of participants admitted to hospital with COVID-19 related illness\|Proportion of participants admitted to ICU with COVID-19 related illness\|Proportion of participants who have died with COVID-19 related illness\|Pharmacokinetics of favipiravir as measured by Clearance (CL)\|Pharmacokinetics of favipiravir as measured by Volume of distribution (V)\|Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)\|Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)\|Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)\|Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)\|Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)\|Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)\|Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)\|Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)\|Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment
NCT05263895	Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation	Not yet recruiting	Phase 1	Mar/03/2022	May/14/2022
Alternative id - C4671008 Interventions - Drug: PF-07321332/ritonavir\|Drug: PF-07321332 Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 12 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Area under the Concentration-Time Curve (AUC)\|Maximum Observed Plasma Concentration (Cmax)\|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)\|Number of Participants With Notable Electrocardiogram (ECG) Values\|Number of Participants With Clinically Notable Vital Signs\|Number of Participants With Clinically Notable Changes in Clinical laboratory\|Number of Participants With Clinically Notable Abnormality in physical examination
NCT05263921	Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants	Not yet recruiting	Phase 1	Mar/11/2022	May/18/2022
Alternative id - C4671024 Interventions - Drug: PF-07321332/ritonavir Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 12 Age - 18 Years to 60 Years (Adult) Outcome measures - Area under curve from time zero to 72 hours post dose\|Peak plasma concentration (Cmax)\|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)\|Number of Participants With Notable Electrocardiogram (ECG) Values\|Number of Participants With Clinically Notable Vital Signs\|Number of Participants With Clinically Notable Changes in Clinical laboratory\|Number of Participants With Clinically Notable Abnormality in physical examination\|Palatability assessment of PF-07321332/ritonavir oral powder mixed with water/applesauce/vanilla pudding
NCT04459702	A Study of Combination Therapies to Treat COVID-19 Infection	Withdrawn	Phase 2	Jul/01/2020	Dec/01/2021
Alternative id - PRG-043 Interventions - Drug: hydroxychloroquine\|Drug: Azithromycin\|Drug: Ritonavir\|Drug: Lopinavir Study type - Interventional Study results - No Results Available Locations - ProgenaBiome, Ventura, California, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores\|Efficacy of Treatment by Time to Non-Infectivity\|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores\|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.\|Safety of Dual Therapy as Measured by Complete Blood Count\|Safety of Quadruple Therapy as Measured by Complete Blood Count\|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio\|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase\|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase\|Safety of Dual Therapy as Measured by Metabolic Panel - AST\|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST\|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT\|Safety of Dual Therapy as Measured by Metabolic Panel ALT\|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio\|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio\|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN\|Safety of Dual Therapy as Measured by Metabolic Panel - BUN\|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide\|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide\|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine\|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine\|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose\|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose\|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin\|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin\|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein\|Safety of Dual Therapy as Measured by Treatment Related SAE\|Safety of Quadruple Therapy as Measured by Treatment Related SAE
NCT04390152	Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19	Recruiting	Phase 1\|Phase 2	Jan/13/2020	Apr/01/2022
Alternative id - BIOXSOMCOV001 Interventions - Drug: Wharton's jelly derived Mesenchymal stem cells.\|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) Study type - Interventional Study results - No Results Available Locations - BioXcellerator, Medellin, Antioquia-CO, Colombia\|Clinical Somer, Rionegro, Antioquia, Colombia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Intergroup mortality difference with treatment\|Number of patients with treatment related adverse events\|Difference in days of mechanical ventilation between groups\|Median reduction of days of hospitalization\|Median reduction of days of oxygen needs\|Difference between "Sequential Organ Failure Assessment" score between groups\|Difference between median Murray score between groups\|Difference in APACHE II score between groups\|Difference in lymphocyte count between groups\|Changes in C reactive protein concentration between groups\|Changes in D dimer concentration\|Changes in ferritin concentration\|Changes in lactate dehydrogenase concentration\|Impact on interleukin 6 concentrations between groups.\|Impact on interleukin 8 concentrations between groups.\|Impact on interleukin 10 concentrations between groups.\|Impact on tumor necrosis factor alpha concentrations between groups.
NCT04321174	COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir	Active, not recruiting	Phase 3	Apr/17/2020	Mar/31/2022
Alternative id - CORIPREV-1 Interventions - Drug: Lopinavir/ritonavir Study type - Interventional Study results - No Results Available Locations - St. Paul's Hospital, Vancouver, British Columbia, Canada\|Sunnybrook Hospital, Toronto, Ontario, Canada\|St. Michael's Hospital, Toronto, Ontario, Canada\|Toronto General Hospital, Toronto, Ontario, Canada Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 123 Age - 18 Months and older (Child, Adult, Older Adult) Outcome measures - Microbiologic evidence of infection\|Adverse events\|Symptomatic COVID-19 disease\|Seropositivity\|Days of hospitalization attributable to COVID-19 disease\|Respiratory failure requiring ventilatory support attributable to COVID-19 disease\|Mortality\|Short-term psychological impact of exposure to COVID-19 disease\|Long-term psychological impact of exposure to COVID-19 disease\|Health-related quality of life
NCT04962022	Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants	Completed	Phase 1	Jul/20/2021	Sep/30/2021
Alternative id - C4671015\|2021-003308-42 Interventions - Drug: PF-07321332/ritonavir\|Drug: Itraconazole Study type - Interventional Study results - No Results Available Locations - Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium Study designs - Allocation: Non-Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 12 Age - 18 Years to 60 Years (Adult) Outcome measures - Maximum Observed Plasma Concentration (Cmax) of PF-07321332/ritonavir when administered alone\|Cmax of PF-07321332/ritonavir when administered with itraconazole\|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07321332/ritonavir when administered alone\|AUCinf of PF-07321332/ritonavir when administered with itraconazole\|Assessment of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)\|Assessment of Participants With Laboratory Abnormalities\|Assessment of Participants With Vital Signs Abnormalities of PF-07321332/ritonavir\|Assessment of Participants With Vital Signs Abnormalities of PF-07321332/ritonavir with itraconazole\|Assessment of Abnormalities in Physical Examination (PE)\|Assessment of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings of PF-07321332/ritonavir\|Assessment of Participants with Clinically Significant ECG findings of PF-07321332/ritonavir with itraconazole
NCT05129475	Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants	Completed	Phase 1	Nov/12/2021	Jan/12/2022
Alternative id - C4671019 Interventions - Drug: PF-07321332/ritonavir\|Drug: Ritonavir Study type - Interventional Study results - No Results Available Locations - New Haven Clinical Research Unit, New Haven, Connecticut, United States Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Basic Science Enrollment - 12 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Maximum Observed Plasma Concentration (Cmax) of PF-07321332\|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07321332\|Area Under the Curve From Time Zero o Last quantifiable concentration (AUClast) of PF-07321332\|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07321332\|Plasma Decay Half-Life (t1/2) of PF-07321332\|Apparent Oral Clearance (CL/F) of PF-07321332\|Apparent Volume of Distribution (Vz/F) of PF-07321332\|Number of Participants With Laboratory Abnormalities\|Number of participants with Treatment-Emergent Adverse Events (TEAEs)\|Number of Participants With Clinically Significant Change From Baseline in Vital Sign\|Number of Participants with Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
NCT05024006	Public Health Emergency: SOLIDARITY TRIAL Philippines	Completed	Not Applicable	Apr/23/2020	Apr/17/2021
Alternative id - SJREB-2020-20 Interventions - Drug: Remdesivir\|Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir\|Drug: Interferon beta-1a\|Drug: Acalabrutinib Study type - Interventional Study results - No Results Available Locations - Baguio General Hospital, Baguio City, Benguet, Philippines\|Cebu Doctor's University Hospital, Cebu City, Cebu, Philippines\|Perpetual Succor Hospital Cebu, Cebu City, Cebu, Philippines\|Vicente Sotto Memorial Medical Center, Cebu City, Cebu, Philippines\|Southern Philippines Medical Center, Davao City, Davao, Philippines\|West Visayas University Medical Center, Iloilo City, Iloilo, Philippines\|Makati Medical Center, Makati City, Metro Manila, Philippines\|Chinese General Hospital, Manila, Metro Manila, Philippines\|Manila Doctors Hospital, Manila, Metro Manila, Philippines\|ManilaMed - Medical Center Philippines, Manila, Metro Manila, Philippines\|San Lazaro Hospital, Manila, Metro Manila, Philippines\|UP - Philippine General Hospital, Manila, Metro Manila, Philippines\|Asian Hospital and Medical Center, Muntinlupa, Metro Manila, Philippines\|Research Institute for Tropical Medicine, Muntinlupa, Metro Manila, Philippines\|San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines\|The Medical City, Pasig City, Metro Manila, Philippines\|Diliman Doctors Hospital, Quezon City, Metro Manila, Philippines\|Fe Del Mundo Medical Center, Quezon City, Metro Manila, Philippines\|Lung Center of the Philippines, Quezon City, Metro Manila, Philippines\|St Luke's Medical Center Quezon City, Quezon City, Metro Manila, Philippines\|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines\|World Citi Medical Center, Quezon City, Metro Manila, Philippines\|Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines\|St Luke's Medical Center Global, Taguig, Metro Manila, Philippines\|Batangas Medical Center, Batangas, Philippines Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 1314 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Duration of hospital stay\|Time to first receiving ventilation
NCT04307693	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Terminated	Phase 2	Mar/11/2020	Apr/30/2020
Alternative id - S2020-0472-0001 Interventions - Drug: Lopinavir/ritonavir\|Drug: Hydroxychloroquine sulfate Study type - Interventional Study results - No Results Available Locations - Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 65 Age - 16 Years to 99 Years (Child, Adult, Older Adult) Outcome measures - Viral load\|Viral load change\|Time to clinical improvement (TTCI)\|Percentage of progression to supplemental oxygen requirement by day 7\|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7\|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission\|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7\|adverse effects\|Concentration of Lopinavir/ritonavir and hydroxychloroquine
NCT04403100	Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"	Recruiting	Phase 3	Jun/03/2020	Feb/01/2021
Alternative id - COVID19_AMB_Brasil Interventions - Drug: Hydroxychloroquine Sulfate Tablets\|Drug: Lopinavir/ Ritonavir Oral Tablet\|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil\|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil\|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil\|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 1968 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of participants who were hospitalized for progression of COVID-19 disease\|Proportion of participants who died due to COVID-19 progression and/ or complications\|Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization\|Time to clinical improvement\|Time to clinical failure\|Hospitalization for any cause\|Proportion of participants who died due to pulmonary complications\|Proportion of participants who died due to cardiovascular complications\|Proportion of participants who presented with adverse events\|Time to improvement on respiratory scale symptoms\|proportion of non-adherent participants to any of study drugs
NCT04394182	Ultra Low Doses of Therapy With Radiation Applicated to COVID-19	Recruiting	Not Applicable	Apr/21/2020	Apr/21/2021
Alternative id - 20.4.1597-GHM Interventions - Radiation: Ultra-Low-dose radiotherapy\|Device: ventilatory support with oxygen therapy\|Drug: Lopinavir/ritonavir\|Drug: Hydroxychloroquine\|Drug: Azithromycin\|Drug: Piperacillin/tazobactam\|Drug: Low molecular weight heparin\|Drug: Corticosteroid injection\|Drug: Tocilizumab Study type - Interventional Study results - No Results Available Locations - Hospital La Milagrosa, GenesisCare, Madrid, Spain\|Hospital Vithas Valencia Consuelo, Valencia, Spain Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 15 Age - 18 Years to 120 Years (Adult, Older Adult) Outcome measures - Oxygen Therapy Status at Day 2\|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2\|Blood Gas Analysis at Day 2\|Blood Test at Day 2\|Oxygen Therapy Status at Day 5\|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5\|Blood Test at Day 5\|Oxygen Therapy Status at Day 7\|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7\|Blood Test at Day 7\|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7\|Recovery time\|COVID-19 status\|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1\|Acute Toxicity

Export (.csv)